WO2009149487A2 - Compounds for treating symptoms associated with parkinson's disease - Google Patents

Compounds for treating symptoms associated with parkinson's disease Download PDF

Info

Publication number
WO2009149487A2
WO2009149487A2 PCT/AT2009/000237 AT2009000237W WO2009149487A2 WO 2009149487 A2 WO2009149487 A2 WO 2009149487A2 AT 2009000237 W AT2009000237 W AT 2009000237W WO 2009149487 A2 WO2009149487 A2 WO 2009149487A2
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
amino acid
compound according
peptides
tyrosine
Prior art date
Application number
PCT/AT2009/000237
Other languages
French (fr)
Other versions
WO2009149487A3 (en
Inventor
Markus Mandler
Frank Mattner
Walter Schmidt
Original Assignee
Affiris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0095208A external-priority patent/AT506820B1/en
Priority claimed from AT0095108A external-priority patent/AT506819B1/en
Priority to BRPI0915134A priority Critical patent/BRPI0915134A2/en
Priority to CA2723995A priority patent/CA2723995A1/en
Priority to EP20090761154 priority patent/EP2310032A2/en
Priority to US12/997,702 priority patent/US20110092436A1/en
Application filed by Affiris Ag filed Critical Affiris Ag
Priority to JP2011512782A priority patent/JP2011522842A/en
Priority to AU2009257170A priority patent/AU2009257170B2/en
Priority to MX2010013647A priority patent/MX2010013647A/en
Priority to CN2009801313674A priority patent/CN102123726A/en
Publication of WO2009149487A2 publication Critical patent/WO2009149487A2/en
Publication of WO2009149487A3 publication Critical patent/WO2009149487A3/en
Priority to IL209896A priority patent/IL209896A0/en
Priority to US13/770,594 priority patent/US20130287807A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Definitions

  • the present invention relates to methods and means for preventing, ameliorating and treat symptoms associated with Parkinson's disease.
  • AD Alzheimer's disease
  • PD Parkinson's Disease
  • a ⁇ plaques amyloid- beta protein
  • APP amyloid precursor protein
  • PD patients are developing pathologic accumulation of alpha-Synuclein (a-Syn, aSyn; forming so called Lewy Bodies) .
  • a-Syn, aSyn alpha-Synuclein
  • Lewy Bodies alpha-Synuclein
  • Both of these molecules are considered to be the major disease causing agents for these neurodegenerative disorders.
  • AD and PD are associated with degeneration of neurons and synaptic connections, deficiency of specific neurotransmitters, and abnormal accumulation of mis- folded proteins, whose non pathogenic paternal proteins play important roles in normal central nervous system functions.
  • DLB/PDD dementia with Lewy bodies or Parkinson's with dementia
  • DLB/PDD is amounting to up to 25% of all dementia cases and has to be considered as second most prominent form of dementia in the elderly.
  • the disease is characterized by the formation of widespread Lewy body pathology associated with extensive amyloid deposition. This presence of widespread Lewy bodies differentiates the DLB/PDD cases from all other types of dementia as well as from other movement disorders.
  • the neurological assessment of DLB/PDD shows prominent abnormalities in attention, in executive functions, in memory as well as behavioural and motoric alterations .
  • aSyn and A ⁇ have distinct, as well as convergent, pathogenic effects on the nervous system. Synucleins are believed to affect motoric function more severely than cognitive function, whereas amyloid ⁇ peptides are described to have opposite effects. In addition, aSYN and A ⁇ could interact more directly by engaging synergistic neurodegenerative pathways. It has been recently shown that different pathologic molecules including A ⁇ , Tau as well as aSyn can mutually exacerbate toxic effects in preclinical disease models and indicate an important function of A ⁇ in different neurodegenerative conditions.
  • Parkinson's disease Current therapies of symptoms of Parkinson's disease involve the administration of dopaminergic agents to patients suffering from said disease.
  • Dopaminergic agents are believed to reduce the symptoms of Parkinson's disease because it is believed that these symptoms are caused by the deprivation of dopamine in the brain.
  • the insufficiency of dopamine in the brain may therefore be compensated by administering to the patient dopaminergic agents, such as dopamine agonists or dopamine precursors, e.g. levodopa.
  • dopaminergic agents such as dopamine agonists or dopamine precursors, e.g. levodopa.
  • There is no established cure for Parkinson's disease which means that the symptoms worsen, necessitating an increase in daily dosage of the medicament as the disease progresses.
  • the chronic use of increased dosages of levodopa leads to the development of motor complications, such as wearing off and involuntary movements (dyskinesia) .
  • the symptoms of motor dysfunction can be improved by levodopa treatment especially combined with other compounds that improve its efficacy.
  • dopaminergic agents have to be administered at regular intervals. Furthermore these agents lead only to an increase of dopaminergeic agents in the patient without removing the cause of the symptoms of Parkinson's disease, namely a-Syn plaques .
  • the present invention relates to a compound comprising a peptide for treating and/or ameliorating motor symptoms of Parkinson ' s disease, said peptide having a binding capacity to an antibody which is specific for an epitope of the amyloid-beta- peptide (A ⁇ ) .
  • compounds capable to induce antibodies directed to the amyloid-beta-peptide and, hence, employable to treat beta-amyloidoses such as Alzheimer's disease can be used to treat and ameliorate the symptoms of Parkinson's disease, in particular the motor symptoms of Parkinson's disease.
  • the antibodies formed by the administration of said compounds reduce surprisingly the amount of a-Syn deposits.
  • Parkinson symptoms refers to those symptoms of the Parkinson's disease which are described in the EMEA Guideline on Clinical Investigation of Medicinal Products in the Treatment of Parkinson's Disease (CPMP/EWP/563/95 Rev.l) that affect the motor behaviour of a patient suffering from said disease and affects autonomic functions of a patient as well.
  • These symptoms include but are not limited to the core symptoms resting tremor, bradykinesia, rigidity, postural instability as well as stooped posture, dystonia, fatigue, impaired fine motor dexterity and motor coordination, impaired gross motor coordination, poverty of movement (decreased arm swing), akathisia, speech problems, such as softness of voice or slurred speech caused by lack of muscle control, loss of facial expression, or "masking", micrographia, difficulty swallowing, sexual dysfunction, drooling.
  • epitope refers to an immunogenic region of an antigen which is recognized by a particular antibody molecule.
  • An antigen may possess one or more epitopes, each capable of binding an antibody that recognizes the particular epitope .
  • peptide having a binding capacity to an antibody which is specific for an epitope of the amyloid-beta-peptide means that said peptide can be bound to an amyloid-beta peptide specific antibody which has been produced by the administration of amyloid-beta peptide or fragments thereof to a mammal. Said peptide having said binding capacity is able to induce the formation of amyloid-beta peptide specific antibodies in a mammal. The latter antibodies bind consequently to the compound of the present invention as well as to the amyloid-beta peptide.
  • said epitope of the amyloid-beta-peptide is selected from the group consisting of DAEFRH, EFRHDSGY, pEFRHDSGY, EVHHQKL, HQKLVF and HQKLVFFAED.
  • the compound according to the present invention may comprise a peptide having one of said amino acid sequences.
  • the compound of the present invention does preferably not comprise a peptide having the amino acid sequence DAEFRH, EFRHDSGY, pEFRHDSGY, EVHHQKL, HQKLVF and HQKLVFFAED, but, however, also binds to amyloid-beta-specific antibodies.
  • phage libraries and peptide libraries can be used.
  • peptide libraries and peptide libraries can be used.
  • all of these methods involve the step of contacting a peptide of a pool of peptides with an amyloid-beta peptide specific antibody.
  • the peptides of the pool binding to said antibody can be isolated and sequenced, if the amino acid sequence of the respective peptide is unknown.
  • peptides which are able to induce the formation of amyloid-beta antibodies in a mammal. These peptides can also be used for reducing symptoms of Parkinson' s disease .
  • Xi is G or an amino acid with a hydroxy group or a negatively charged amino acid, preferably glycine (G) , glutamic acid (E) , tyrosine (Y) , serine (S) or aspartic acid (D) ,
  • X2 is a hydrophobic amino acid or a positively charged amino acid, preferably asparagine (N), isoleucine (I), leucine (L), valine (V) , lysine (K) , tryptophane (W) , arginine (R) , tyrosine (Y) , phenylalanine (F) or alanine (A) ,
  • X3 is a negatively charged amino acid, preferably aspartic acid (D) or glutamic acid (E),
  • X 4 is an aromatic amino acid or a hydrophobic amino acid or leucine (L), preferably tyrosine (Y), phenylalanine (F) or leucine (L) ,
  • X5 is histidine (H) , lysine (K) , tyrosine (Y) , phenylalanine (F) or arginine (R) , preferably histidine (H) , phenylalanine (F) or arginine (R) , and
  • Xg is not present or serine (S) , threonine (T) , asparagine (N) , glutamine (Q) , aspartic acid (D) , glutamic acid (E) , arginine (R), isoleucine (I), lysine (K), tyrosine (Y), or glycine (G) , preferably threonine (T) , asparagine (N) , aspartic acid (D), arginine (R), isoleucine (I) or glycine (G),
  • X7 is not present or any amino acid, preferably proline (P), tyrosine (Y) , threonine (T) , glutamine (Q) , alanine (A) , histidine (H) or serine (S), preferably EIDYHR, ELDYHR, EVDYHR, DIDYHR, DLDYHR, DVDYHR, DI-DYRR, DLDYRR, DVDYRR, DKELRI, DWELRI, YREFFI, YREFRI, YAEFRG, EAEFRG, DYEFRG, ELEFRG, DRELRI, DKELKI, DRELKI, GREFRN, EYEFRG, DWEFRDA, SWEFRT, DKELR, SFEFRG, DAEFRWP, DNEFRSP, GSEFRDY, GAEFRFT, SAEFRTQ, SAEFRAT, SWEFRNP, SWEFRLY, SWELRQA, SVEFRYH, SYEFRHH, SQ
  • X 1 is isoleucine (I) or valine (V),
  • X2 is tryptophan (W) or tyrosine (Y) ,
  • X 3 is threonine (T) , valine (V) , alanine (A) , methionine (M) , glutamine (Q) or glycine (G) ,
  • X4 is proline (P) , alanine (A) , tyrosine (Y) , serine (S) , cysteine (C) or glycine (G) ,
  • X 5 is proline (P), leucine (L), glycine (G) or cysteine (C),
  • XQ is cysteine (C) , n, m and o are, independently, 0 or 1, preferably IRWDTP(C), VRWDVYP(C), IRYDAPL(C), IRYDMAG(C), IRWDTSL(C), IRWDQP(C), IRWDG(C) or IRWDGG(C) .
  • the peptide of the compound of the present invention may comprise the amino acid sequence
  • X2 is arginine (R) or glutamic acid (E) ,
  • X3 is alanine (A) , histidine (H) , lysine (K) , leucine (L) , tyrosine (Y) or glycine (G) ,
  • X 4 is proline (P) , histidine (H) , phenylalanine (F) or glutamine (Q) or Cysteine
  • X5 is cysteine (C)
  • n and m are, independently, 0 or 1, preferably EVWHRHQ(C), ERWHEKH(C), EVWHRLQ(C), ELWHRYP(C), ELWHRAF(C), ELWHRA(C), EVWHRG(C), EVWHRH(C) and ERWHEK (C) , preferably EVWHRHQ(C), ERWHEKH(C), EVWHRLQ(C), ELWHRYP(C) or EL- WHRAF(C) .
  • the peptide comprises the amino acid sequence QDFRHY(C), SEFKHG(C), TSFRHG(C), TSVFRH(C), TPFRHT(C), SQFRHY(C), LMFRHN(C), SAFRHH(C), LPFRHG(C), SHFRHG(C), ILFRHG(C), QFKHDL(C), NWFPHP(C), EEFKYS(C), NELRHST(C), GEMRHQP(C), DTYFPRS(C), VELRHSR(C), YSMRHDA(C), AANYFPR(C), SPNQFRH(C), SSSFFPR(C), EDWFFWH(C), SAGSFRH(C), QVMRHHA(C), SEFSHSS(C), QPNLFYH(C), ELFKHHL(C), TLHEFRH(C), ATFRHSP(C), AP- MYFPH(C), TYFSHSS(C), QPNLFYH(
  • Xi is serine (S) , alanine (A) or cysteine (c) ,
  • X2 is serine (S) , threonine (T) , glutamic acid (E) , aspartic acid (D), glutamine (Q) or methionine (M),
  • X 3 is isoleucine (I), tyrosine (Y), methionine (M) or leucine (L)
  • X 4 is leucine (L) , arginine (R) , glutamine (Q) , tryptophan (W), valine (V), histidine (H), tyrosine (Y), isoleucine (I), lysine (K) methionine (M) or phenylalanine (F)
  • I isoleucine
  • Y isoleucine
  • M methionine
  • L leucine
  • arginine R
  • glutamine Q
  • W tryptophan
  • V valine
  • V histidine
  • H histidine
  • tyrosine Y
  • isoleucine I
  • K methionine
  • M methionine
  • F phenylalanine
  • X5 is alanine (A), phenylalanine (F) histidine (H) , aspar- agine (N) , arginine (R) , glutamic acid (E isoleucine (I ) , glutamine (Q) , aspartic acid (D) , proline P) or tryptophane (W), glycine (G)
  • Xg is any amino acid residue
  • X 7 is cysteine (C)
  • m and n are, independently, 0 or 1, preferably SGEYVFH(C), SGQLKFP(C), SGQIWFR(C), ' SGEIHFN(C; GQIWFIS(C), GQIIFQS(C), GQIRFDH(C), GEMWFAL(C), GELQFPP(C),
  • Xi is serine (S) , threonine (T) or cysteine (C) ,
  • X 2 is glutamine (Q) , threonine (T) or methionine (M) ,
  • X 3 is lysine (K) or arginine (R) ,
  • X4 is leucine (L) , methionine (M) ,
  • X5 is tryptophane (W), tyrosine (Y), phenylalanine (F) or isoleucine (I) ,
  • X ⁇ is asparagine (N) , glutamic acid (E) , alanine (A) or cysteine (C) ,
  • X 7 is cysteine (C) , n and m are, independently, 0 or 1 , preferably SHTRLYF(C), HMRLFFN(C), SHQRLWF(C), HQKMIFA(C), HMRMYFE(C), THQRLWF(C) or HQKMIF(C) .
  • the peptide comprises the amino acid sequence AIPLFVM(C), KLPLFVM(C), QLPLFVL(C) or NDAKIVF (C) .
  • the compound according to the present invention is preferably a polypeptide/peptide and comprises 4 to 30 amino acid resi- dues, preferably 5 to 25 amino acid residues, more preferably 5 to 20 amino acid residues.
  • the compound of the present invention may also be part of a polypeptide comprising 4 to 30 amino acid residues.
  • mimotopes refers to a molecule which has a conformation that has a topology eguivalent to the epitope of which it is a mimic.
  • the mimotope binds to the same antigen- binding region of an antibody which binds immunospecifically to a desired antigen.
  • the mimotope will elicit an immunological response in a host that is reactive to the antigen to which it is a mimic.
  • the mimotope may also act as a competitor for the epitope of which it is a mimic in in vitro inhibition assays (e.g.
  • a mimotope of the present invention may not necessarily prevent or compete with the binding of the epitope of which it is a mimic in an in vitro inhibition assay although it is capable to induce a specific immune response when administered to a mammal.
  • the compounds of the present invention comprising such mimotopes (also those listed above) have the advantage to avoid the formation of autoreactive T-cells, since the peptides of the compounds have an amino acid sequence which varies from those of naturally occurring amyloid- beta peptide.
  • the mimotopes/peptides of the present invention can be synthetically produced by chemical synthesis methods which are well known in the art, either as an isolated peptide or as a part of another peptide or polypeptide.
  • the peptide mimotope can be produced in a microorganism which produces the peptide mimotope which is then isolated and if desired, further purified.
  • the peptide mimotope can be produced in microorganisms such as bacteria, yeast or fungi, in eukaryote cells such as a mammalian or an insect cell, or in a recombinant virus vector such as adenovirus, poxvirus, herpesvirus, Simliki forest virus, baculovirus, bacteriophage, Sindbis virus or sendai virus.
  • Suitable bacteria for producing the peptide mimotope include E.coli, B.subtilis or any other bacterium that is capable of expressing peptides such as the peptide mimotope.
  • Suitable yeast types for expressing the peptide mimotope include Saccharomyces cere- visiae, Schizosaccharomyces pombe, Candida, Pichia pastoris or any other yeast capable of expressing peptides. Corresponding methods are well known in the art. Also methods for isolating and purifying recombinantly produced peptides are well known in the art and include e.g. as gel filtration, affinity chromatography, ion exchange chromatography etc..
  • a fusion polypeptide may be made wherein the peptide mimotope is transla- tionally fused (covalently linked) to a heterologous polypeptide which enables isolation by affinity chromatography.
  • Typical heterologous polypeptides are His-Tag (e.g. His 6 ; 6 histidine residues), GST-Tag (Glutathione-S-transferase) etc..
  • His-Tag e.g. His 6 ; 6 histidine residues
  • GST-Tag Glutathione-S-transferase
  • the fusion polypeptide may comprise a cleavage site at the junction between the peptide mimotope and the heterologous polypeptide.
  • the cleavage site consists of an amino acid sequence that is cleaved with an enzyme specific for the amino acid sequence at the site (e.g. proteases) .
  • the mimotopes of the present invention may also be modified at or nearby their N- and/or C-termini so that at said positions a cysteine residue is bound thereto.
  • terminally positioned (located at the N- and C-termini of the peptide) cysteine residues are used to cyclize the peptides through a disulfide bond.
  • the mimotopes of the present invention may also be used in various assays and kits, in particular in immunological assays and kits. Therefore, it is particularly preferred that the mimotope may be part of another peptide or polypeptide, particularly an enzyme which is used as a reporter in immunological assays.
  • reporter enzymes include e.g. alkaline phosphatase or horseradish peroxidase.
  • the mimotopes according to the present invention preferably are antigenic polypeptides which in their amino acid sequence vary from the amino acid sequence of A ⁇ or of fragments of A ⁇ .
  • the inventive mimotopes may not only comprise amino acid substitutions of one or more naturally occurring amino acid residues but also of one or more non-natural amino acids (i.e. not from the 20 "classical” amino acids) or they may be completely assembled of such non-natural amino acids.
  • inventive antigens which induce antibodies directed and binding to A ⁇ l-40/42, A ⁇ pE3-40/42, A ⁇ 3-40/42, A ⁇ ll-40/42, A ⁇ pEll-40/42 and A ⁇ l4-40/42 may be assembled of D- or L- amino acids or of combinations of DL- amino acids and, optionally, they may have been changed by further modifications, ring closures or derivatizations .
  • Suitable antibody-inducing antigens may be provided from commercially available peptide libraries.
  • these peptides are at least 7 amino acids, and preferred lengths may be up to 16, preferably up to 14 or 20 amino acids (e.g. 5 to 16 amino acid residues) . According to the invention, however, also longer peptides may very well be employed as antibody- inducing antigens. Furthermore the mimotopes of the present invention may also be part of a polypeptide and consequently comprising at their N- and/or C-terminus at least one further amino acid residue.
  • peptide libraries are suitable, for instance produced by means of combinatorial chemistry or obtained by means of high throughput screening techniques for the most varying structures (Display: A Laboratory Manual by Carlos F. Barbas (Editor), et al.; Willats WG Phage display: practicalities and prospects. Plant MoI. Biol. 2002 Dec; 50 ( 6) : 837-54) .
  • anti-A ⁇ l-40/42- , -A ⁇ pE3-40/42-, -A ⁇ 3-40/42-, -A ⁇ ll-40/42- A ⁇ pEll-40/42- and A ⁇ l4-40/42-antibody-inducing antigens based on nucleic acids may be employed, and these, too, may be found with the most varying (oligonucleotide) libraries (e.g. with 2-180 nucleic acid residues) (e.g. Burgstaller et al., Curr. Opin. Drug Discov. Dev. 5(5) (2002), 690-700; Famulok et al., Ace. Chem. Res.
  • the nucleic acid backbone can be provided e.g. by the natural phosphor-diester compounds, or also by phosphorotioates or combinations or chemical variations (e.g. as PNA), wherein as bases, according to the invention primarily U, T, A, C, G, H and mC can be employed.
  • the 2 ' -residues of the nucleotides which can be used according to the present invention preferably are H, OH, F, Cl, NH 2 , 0-methyl, O-ethyl, O-propyl or O-butyl, wherein the nucleic acids may also be differently modified, i.e. for instance with protective groups, as they are commonly employed in oligonucleotide synthesis.
  • aptamer-based antibody-inducing antigens are also preferred antibody-inducing antigens within the scope of the present invention.
  • the compound is coupled to a pharmaceutically acceptable carrier, preferably KLH (Keyhole Limpet Hemocyanin) , tetanus toxoid, albumin-binding protein, bovine serum albumin, a den- drimer (MAP; Biol. Chem. 358: 581), peptide linkers (or flanking regions) as well as the adjuvant substances described in Singh et al., Nat. Biotech.
  • KLH Keyhole Limpet Hemocyanin
  • tetanus toxoid albumin-binding protein
  • bovine serum albumin bovine serum albumin
  • MAP den- drimer
  • peptide linkers or flanking regions
  • the vaccine composition may be formulated with an adjuvant, preferably a low soluble aluminium composition, in particular aluminium hydroxide.
  • adjuvants like MF59 aluminium phosphate, calcium phosphate, cytokines (e.g., IL-2, IL-12, GM-CSF), saponins (e.g., QS21), MDP derivatives, CpG oligos, LPS, MPL, poly- phosphazenes, emulsions (e.g., Freund's, SAF), liposomes, viro- somes, iscoms, cochleates, PLG microparticles, poloxamer particles, virus-like particles, heat-labile enterotoxin (LT) , cholera toxin (CT), mutant toxins (e.g., LTK63 and LTR72), microparticles and/or polymerized liposomes may be used.
  • cytokines e.g., IL-2, IL-12, GM-CSF
  • saponins e.g., QS21
  • MDP derivatives e.g., C
  • the compound of the present invention is preferably bound to the carrier or adjuvant via a linker, which is selected from the group consisting of NHS-poly (ethylene oxide) (PEO) (e.g. NHS- PEO 4 -maleimide) .
  • PEO poly (ethylene oxide)
  • a vaccine which comprises the present compound (mimotope, peptide) and the pharmaceutically acceptable carrier may be administered by any suitable mode of application, e.g. i.d., i.v., i.p., i.m., intranasally, orally, subcutaneously, etc. and in any suitable delivery device (O'Hagan et al . , Nature Reviews, Drug Discovery 2 (9), (2003), 727-735).
  • the compound of the present invention is preferably formulated for intravenous, subcutaneous, intradermal or intramuscular administration (see e.g. "Handbook of Pharmaceutical Manufacturing Formulations", Sar- faraz Niazi, CRC Press Inc, 2004) .
  • the medicament (vaccine) according to the present invention contains the compound according to the invention in an amount of from 0.1 ng to 10 mg, preferably 10 ng to 1 mg, in particular 100 ng to 100 ⁇ g, or, alternatively, e.g. 100 fmol to 10 ⁇ mol, preferably 10 pmol to 1 ⁇ mol, in particular 100 pmol to 100 nr ⁇ ol.
  • the vaccine may also contain auxiliary substances, e.g. buffers, stabilizers etc.
  • the motor symptoms of Parkinson's disease are selected from the group consisting of resting tremor, Bradykinesia, rigidity, postural instability, stooped posture, dystonia, fatigue, impaired fine motor dexterity and motor coordination, impaired gross motor coordination, poverty of movement (decreased arm swing) , akathisia, speech problems, loss of facial expression, micro- graphia, difficulty swallowing, sexual dysfunction and drooling.
  • Another aspect of the present invention relates to the use of a compound according to the present invention for the manufacture of a medicament for treating, preventing and/or ameliorating motor symptoms of Parkinson's disease.
  • Yet another aspect of the present invention relates to a method for treating and/or ameliorating symptoms, in particular motor symptoms, of Parkinson's disease.
  • Fig. 1 shows the individualised peptide members of library 4 used for the present screening process.
  • Fig. 2 shows an inhibition assay with mimotopes for DAEFRH.
  • Fig. 3 shows another inhibition assay with other mimotopes for DAEFRH.
  • Figs. 4 and 5 describe the results of inhibition assays performed with mimotope peptides according to the present invention.
  • Figs. 6 to 9 show the results of inhibition assays performed with mimotope peptides 4011-4018, 4019-4025, 4031-4038 and 4061- 4064, respectively.
  • Fig. 10 shows binding of monoclonal antibody MV-001 to specific peptides and recombinant proteins
  • Fig. 11 shows binding of monoclonal antibody MV-003 to specific peptides and recombinant proteins
  • Fig. 12 shows binding of monoclonal antibody MV-004 to specific peptides and recombinant proteins
  • Fig. 13 shows typical binding assays with mimotopes for ⁇ - amyloid and N-terminally truncated and/or posttranslationally modified ⁇ -amyloid fragments
  • Fig. 14 shows typical inhibition assays with mimotopes for ⁇ -amyloid and N-terminally truncated and/or posttranslationally modified ⁇ -amyloid fragments
  • Fig. 15 shows examples for in vivo characterisations of the immune response elicited by mimotope vaccination (injected pep- tide/irrelevant peptide) ;
  • Fig. 16 shows examples for in vivo characterisation of the immune response elicited by mimotope vaccination against Amyloid Beta fragments
  • Fig. 17 shows examples for in vivo characterisation of the immune response elicited by mimotope vaccination against full length
  • Fig. 18 shows areas occupied by amyloid plaques.
  • Tg2576 were injected 6 times with mimotope vaccines adjuvanted with aluminium hydroxide (ALUM) by s.c. inoculation at monthly intervals.
  • Control mice received PBS-ALUM only. Area occupied by amyloid plaques shown as percent of the control group.
  • Fig. 19 shows areas occupied by amyloid plaques.
  • Tg2576 were injected 6 times with AFFITOPE vaccines adjuvanted with aluminium hydroxide (ALUM) by s.c. inoculation at monthly intervals.
  • Control mice received PBS-ALUM only. Area occupied by amyloid plaques shown as percent of the control group.
  • Fig. 20 shows binding of monoclonal antibody MV-002 to specific peptides and recombinant proteins.
  • Fig. 21 shows typical binding assays with mimotopes for ⁇ - amyloid and N-terminally truncated and/or posttranslationally modified ⁇ -amyloid fragments.
  • Fig. 22 shows typical inhibition assays with mimotopes for ⁇ -amyloid and N-terminally truncated and/or posttranslationally modified ⁇ -amyloid fragments.
  • Fig. 23 shows examples for in vivo characterisations of the immune response elicited by mimotope vaccination (injected pep- tide/irrelevant peptide) .
  • Fig. 24 shows examples for in vivo characterisation of the immune response elicited by mimotope vaccination against Amyloid Beta fragments and sAPP-alpha.
  • Fig. 25 shows examples for in vivo characterisation of the immune response elicited by mimotope vaccination against full length A ⁇ 40/42.
  • Fig. 26 shows areas occupied by amyloid plaques.
  • Tg2576 were injected 6 times with mimotope vaccines adjuvanted with aluminium hydroxide (ALUM) by s.c. inoculation at monthly intervals.
  • Control mice received PBS-ALUM only. Area occupied by amyloid plaques shown as percent of the control group.
  • Fig. 27 shows a-synuclein positive inclusions.
  • A.. Control treated animal; B.. AD mimotope treated animal; A and B display cortical sections stained for a-synuclein. Positive staining shows neuronal cells including pyramidal and non-pyramidal neurons. Arrows indicate two typical examples for inclusions in A and B.
  • Fig. 28 shows neuronal density.
  • Pictures display cortical sections stained for NeuN. positive staining shows neuronal cells including pyramidal and non-pyramidal neurons.
  • A. indicates a control treated animal;
  • B.. Shows an AD mimotope treated animal respectively.
  • C and D.. shows the the number of NeuN positive neurons in the cortex and hippocampus.
  • Exampl e 1 Genera ti on of monocl onal an tibodies (mAb) to detect AB 42-derived peptide species wi th free N-terminus (free as- parti c a cid a t the N-terminus) Mice are vaccinated with the ⁇ mer peptide DAEFRH (natural N- terminal A ⁇ 42 sequence) linked to the protein bovine serum albumin BSA (to make use of the hapten-carrier-effect ) , emulsified in CFA (first injection) and IFA (booster injections) .
  • DAEFRH naturally N- terminal A ⁇ 42 sequence
  • BSA protein bovine serum albumin BSA
  • DAEFRH- peptide-specific, antibody-producing hybridomas are detected by ELISA (DAEFRH-peptide-coated ELISA plates) .
  • Peptide SEVKMDAEFRH naturally N-terminally prolonged sequence, APP-derived, containing the A ⁇ 42-derived sequence DAEFRH
  • hybridomas recognizing the prolonged peptide are excluded because they do not distinguish between A ⁇ 42-derived peptides with free aspartic acid at the N-terminus and APP- derived peptide DAEFRH without free aspartic acid.
  • FIGS 2 and 3 describe the results of inhibition assays performed with mimotope peptides included in and obtained from the 5 libraries (as described in WO 2004/062556) .
  • the mimotope peptides compete with the original epitope for recognition by the monoclonal antibody.
  • Original epitope and mimotope peptides contain an additional C at the C-terminus for coupling to a protein carrier (if desired) .
  • ELISA plates (Nunc Maxisorp) are coated with the original peptide epitope DAEFRH (C-terminally prolonged with C and coupled to bovine serum albumin BSA) at a concentration of 0.1 ⁇ g/ml peptide-BSA (100 ⁇ l/well, 12h, 4°C) . After blocking with PBS/BSA 1% (200 ⁇ l/well, 12h, 4°C) , the plates are washed 3x times with PBS/Tween. Then, biotinylated monoclonal antibody (1:2000, 50 ⁇ l/well) and peptides (50 ⁇ l/well) at 50, 5, 0.5, 0.05, 0.005, and 0.0005 ⁇ g/ml are added for 20 min.
  • HRP horseradish peroxidase
  • streptavidin 100 ⁇ l/well, 30 min, RT
  • the plates are washed 5x times with PBS/Tween and are incubated with ABTS + H 2 O 2 (0.1% w/v, 10 to 45 min) and the reaction is stopped with citric acid followed by photometric evaluation (wavelength 405 nm) .
  • peptide 1737 DAEFRH can compete with BSA-coupled, plate-bound peptide DAEFRH and thus inhibits recognition by the monoclonal antibody. Furthermore, it is shown that peptide 3003 is not able to inhibit binding of the monoclonal antibody to the original epitope. In contrast, peptides 3001, 3002, 3004, 3005, 3006, and 3007 (to a different extent) block epitope recognition. Whereas peptide 3004 is only inhibitory at a high concentration (50 ⁇ g/ml), peptides 3001, 3006, and 3007 are strongly inhibitory with an IC 50 of less than 0.5 ⁇ g/ml. Peptides 3002 and 3005 are "intermediate" inhibitors with an IC 50 of more than 0.5 ⁇ g/ml.
  • peptide 1737 DAEFRH can successfully compete with BSA-coupled, plate-bound peptide DAEFRH for monoclonal antibody recognition in an additionally performed, independent experiment. Furthermore, it is shown that peptides 3010 and 3011 are not inhibitory at the concentrations tested, whereas peptides 3008 and 3009 are (relatively) weak inhibitors with an IC 50 of less than 5 ⁇ g/ml.
  • Table 1 briefly summarizes the inhibitory capacity of mimo- topes included in and obtained from libraries (as described) :
  • FIGS 4 and 5 describe the results of inhibition assays performed with mimotope peptides included in and obtained from the 5 libraries as described in WO 2004/062556.
  • the mimotope peptides compete with the orginal epitope for recognition by the monoclonal antibody.
  • Original epitope and mimotope peptides contain an additional C at the C-terminus (position 7) for coupling to a protein carrier (if desired) .
  • ELISA plates (Nunc Maxisorp) are coated with the original peptide epitope DAEFRH (C-terminally prolonged with C and coupled to bovine serum albumin BSA) at a concentration of 0.1 ⁇ g/ml peptide-BSA (100 ⁇ l/well, 12h, 4°C) . After blocking with PBS/BSA 1% (200 ⁇ l/well, 12h, 4°C), the plates are washed 3x times with PBS/Tween. Then, biotinylated monoclonal antibody (1:2000, 50 ⁇ l/well) and peptides (50 ⁇ l/well) at different concentrations are added for 20 min. at 37°C.
  • the plates are washed 3x times with PBS/Tween and are incubated with horseradish peroxidase (HRP) -labeled streptavidin (100 ⁇ l/well, 30 min, RT) .
  • HRP horseradish peroxidase
  • the plates are washed 5x times with PBS/Tween and are incubated with ABTS + H 2 O 2 (0.1% w/v, 10 to 45 min) and the reaction is stopped with citric acid followed by photometric evaluation (wavelength 405 nm) .
  • peptide 1737 DAEFRH can compete with BSA-coupled, plate-bound peptide DAEFRH and thus inhibits recognition by the monoclonal antibody. Furthermore, it is shown that peptide 4004 is not able to inhibit binding of the monoclonal antibody to the original epitope. In contrast, peptides 4002 and 4003 (to a different extent) block epitope recognition. Whereas peptide 4003 is only inhibitory at a relatively high concentration (10 ⁇ g/ml), peptide 4002 is strongly inhibitory with an IC 50 of less than 0.4 ⁇ g/ml.
  • peptide 1737 DAEFRH can successfully compete with BSA-coupled, plate-bound peptide DAEFRH for monoclonal antibody recognition in an additionally performed, independent experiment. Furthermore, it is shown that peptide 1234 is hardly inhibitory at the concentrations tested, whereas peptides 1235, 1236, 1237, 1238, 1239 and 1241 (to a different extent) block epitope recognition. Peptides 1235, 1238 and 1241 are strong inhibitors with an IC 50 of less than 0.5 ⁇ g/ml, whereas peptides 1236 and 1237 are (relatively) weak inhibitors with an IC 50 of more than 5 ⁇ g/ml. Peptide 1239 is an intermediate inhibitor with an ICc 1Q of more than 0.5 ⁇ g/ml.
  • Table 2 briefly summarizes the inhibitory capacity of mimo- topes included in and obtained from libraries (as described) :
  • the mimotopes are obtained as described in WO 2006/005707.
  • the following peptides are used for the following assays: Peptide 1737 DAEFRH original epitope Peptide 4011 DAEFRWP 7mer s Peptide 4012 DNEFRSP 7mer s Peptide 4013 GSEFRDY 7mer m Peptide 4014 GAEFRFT 7mer m
  • ELISA plates (Nunc Maxisorp) are coated with the original peptide epitope DAEFRH (C-terminally prolonged with C and coupled to bovine serum albumin BSA) at a concentration of 0.1 ⁇ g/ml peptide-BSA (100 ⁇ l/well, 12h, 4°C) . After blocking with PBS/BSA 1% (200 ⁇ l/well, 12h, 4°C), the plates are washed 3x times with PBS/Tween. Then, biotiriylated monoclonal antibody (1:2000, 50 ⁇ l/well) and peptides (50 ⁇ l/well) at different concentrations are added for 20 min. at 37°C.
  • the plates are washed 3x times with PBS/Tween and are incubated with horseradish peroxidase (HRP) -labeled streptavidin (100 ⁇ l/well, 30 min, RT) .
  • HRP horseradish peroxidase
  • the plates are washed 5x times with PBS/Tween and are incubated with ABTS + H 2 O 2 (0.1% w/v, 10 to 45 min) and the reaction is stopped with citric acid followed by photometric evaluation (wavelength 405 ran) .
  • peptide 1737 DAEFRH can compete with BSA-coupled, plate- bound peptide DAEFRH and thus inhibits recognition by the monoclonal antibody. Furthermore, it is shown that peptides 4012 DNEFRSP, 4013 GSEFRDY, and 4014 GAEFRFT are able to moderately inhibit binding of the monoclonal antibody to the original epitope. In contrast, peptides 4011 DAEFRWP, 4015 SAEFRTQ, 4016 SAEFRAT, 4017 SWEFRNP, and 4018 SWEFRLY (to a different extent) strongly block epitope recognition.
  • peptide 1737 DAEFRH can successfully compete with BSA-coupled, plate-bound peptide DAEFRH for monoclonal antibody recognition in an additionally performed, independent experiment. Furthermore, it is shown that peptide 4019 SWFRNP is not inhibitory at the concentrations tested, whereas peptides 4020 SWELRQA, 4021 SVEFRYH, 4022 SYEFRHH, 4023 SQEFRTP, 4024 SSERFVS and 4025 DWEFRD (to a different extent) block epitope recognition.
  • Peptides 4021, 4022, 4023, 4024 and 4025 are strong inhibitors with an IC50 of less than 0.5 ⁇ g/ml, whereas peptide 4020 is an intermediate inhibitor with an IC50 of more than 0.5 ⁇ g/ml.
  • peptide 1737 DAEFRH can successfully compete with BSA-coupled, plate-bound peptide DAEFRH for monoclonal antibody recognition in a 3rd independent experiment. Furthermore, it is shown that peptides 4037 VPTSALA and 4038 ATYAYWN are not inhibitory at the _ o ⁇ — concentrations tested, whereas peptides 4031 DAELRY, 4032 DWELRQ, 4033 SLEFRF, 4034 GPEFRW, 4035 GKEFRT and 4036 AYEFRH
  • Peptides 4031, 4032, 4033, 4034 and 4035 are relatively strong inhibitors with an IC50 of less than 0.5 ⁇ g/ml, whereas peptide 4036 is a
  • Example 5 Inhibition assay with defined 5mer peptides : non- natural amino acids
  • the 5mer peptide 1238 DKELR may be used as epitope in a mimotope-based Alzheimer vaccine (see PCT/EP04/00162) .
  • amino acids of the original 5mer epitope are replaced by non-natural amino acids: L is replaced by the non-natural amino acids tBuGly, NIe, Nva, or Cha.
  • peptide 1737 DAEFRH can successfully. compete with BSA-coupled, plate-bound peptide DAEFRH for monoclonal antibody recognition in a 4th independent experiment. Furthermore, it is shown that peptide 4061 DKE(tBuGly)R is not inhibitory at the concentrations tested. Interestingly, peptides 4062 DKE(NIe)R, 4063 DKE ((Nva) R, and 4064 DKE (Cha) R (to a different extent) block epitope recognition. Peptides 4062, 4063, and 4064 are relatively weak inhibitors with an IC50 of more than 0.5 ⁇ g/ml.
  • Example 6 Generation of monoclonal antibodies to specifically detect Si-amyloid and N-terminally truncated and/or post- translationally modified ⁇ -amyloid fragments .
  • the antibodies used for the mimotope identification detect amino acid sequences derived from human A ⁇ but do not bind to full length human APP.
  • the antibody may be a monoclonal or polyclonal antibody preparation or any antibody part or derivative thereof, the only prerequisite is that the antibody molecule specifically recognises at least one of the epitopes mentioned above (derived from human A ⁇ ), but does not bind to full length human APP.
  • Example 6a Generation of monoclonal antibody MV-OOl
  • Human AB40/42 (recombinant protein) was used as positive control peptide: hybridomas recognizing the recombinant protein immobilised on ELISA plates were included because they are binding both peptide and full length A ⁇ specifically. P1454 (Human A ⁇ 33-40) was used as negative control peptide. Furthermore hybridomas were tested against p4373. Only hybridomas with no or limited p4373 binding were used for further antibody development .
  • the Hybridoma clone (MV-OOl (internal name 824; IgGl) was purified and analysed for specific detection of pl253, p4371, p4373, pl454 and A ⁇ respectively.
  • MV-001 recognised the injected epitope (pl253) as well as the specific epitope (p4371) and full length A ⁇ protein (recombinant protein; obtained from Bachem AG, Bubendorf, Switzerland) in ELISA. It however did not detect pl454 in ELISA.
  • the MV-001 antibodies basically failed to detect the peptide p4373 encoding the pyroglutamate version of A ⁇ 3-10 (30 times lower titer than the original epitopes) .
  • Example 6b Generation of monoclonal antibody MV-003
  • the Hybridoma clone (MV-003 (internal name D129; IgGl) was purified and analysed for specific detection of pl253, p4371, p4373, pl454 and A ⁇ respectively.
  • MV-003 recognized the injected epitope (p4373) but failed to detect pl454, pl253 or full length A ⁇ protein (recombinant protein; obtained from Bachem AG, Buben- dorf, Switzerland) in ELISA.
  • the MV-003 antibodies failed to detect the peptide p4371 encoding the normal version of AB3-10 (15 times lower titer than the original epitope) .
  • Example 6c Generation of monoclonal antibody MV-004
  • the Hybridoma clone (MV-004 (internal name B204; IgGl) was purified and analysed for specific detection of p4372, p4376, p4378, pl454 and A ⁇ respectively.
  • MV-004 recognized the injected epitope (p4372) but failed to detect pl454, p4376 and p4378 as well as full length A ⁇ protein (recombinant protein; obtained from Bachem AG, Bubendorf, Switzerland) in ELISA.
  • the failure to detect p4376, p4378 demonstrates specificity for the free N- terminus at position aall in truncated A ⁇ .
  • Example 6d Generation of monoclonal antibodies to specifically detect ⁇ -amyloid and ⁇ -terminally truncated and/or post- translationally modified ⁇ -amyloid fragments - monoclonal antibody hW-002
  • the antibodies used for the mimotope identification according to the present invention detect amino acid sequences derived from human A ⁇ but do not bind to full length human APP.
  • the an- tibody may be a monoclonal or polyclonal antibody preparation or any antibody part or derivative thereof, the only prerequisite is that the antibody molecule specifically recognises at least one of the epitopes mentioned above (derived from human A ⁇ ) , but does not bind to full length human APP.
  • the mimotopes are identified and further characterised with such monoclonal antibodies and peptide libraries.
  • a monoclonal antibody derived from the fusion of experiment Alz-9 was generated: C57/B16 mice were immunized repeatedly with original A ⁇ epitope HQKLVFC coupled to KLH (Keyhole Limpet Hemo- cyanin) and Alum (Aluiminium Hydroxide) as adjuvant. p4377 pep- tide-specific, antibody-producing hybridomas were detected by ELISA (p4377-peptide-coated ELISA plates) . Human A ⁇ 40/42 (recombinant protein) was used as positive control peptide: hybridomas recognizing the recombinant protein immobilised on ELISA plates were included because they were binding both peptide and full length A ⁇ specifically.
  • pl454 Human A ⁇ 33-40 was used as negative control peptide. Furthermore hybridomas were tested against p4374, pl323 and sAPP-alpha. Only hybridomas with good p4374, and pl323 binding and a lack of sAPP-alpha binding were used for further antibody development.
  • the Hybridoma clone MV-002 (internal name A115; IgG2b) was purified and analysed for specific detection of pl323, p4374, p4377, pl454, A ⁇ and sAPP-alpha respectively.
  • MV-002 recognized the epitopes pl323 as well as p4377 and full length A ⁇ protein (recombinant protein; obtained from Bachem AG, Bubendorf, Switzerland) in ELISA. It however did not detect pl454 in ELISA.
  • the MV-002 antibodies failed to detect sAPP-alpha but bound specifically to the peptide p4374 encoding the pyro- glutamate version of A ⁇ ll-19.
  • Example 7 Phage Display, in vitro binding and inhibition ELISA
  • Phage Display libraries used in this example were: Ph.D. 7: New England BioLabs E8102L (linear 7mer library) . Phage Display was done according to manufacturer' s protocol (www. neb . com) .
  • Peptides derived from Phage Display as well as variants thereof were coupled to BSA and bound to ELISA plates (i ⁇ M; as indicated in the respective figures) and subsequently incubated with the monoclonal antibody that was used for the screening procedure to analyse binding capacity of identified peptides.
  • Inhibiting as well as non-inhibiting peptides were coupled to KLH and injected into mice (wildtype C57/B16 mice; subcutaneous injection into the flank) together with an appropriate adjuvant (aluminium hydroxide) . Animals were vaccinated 3-6 times in biweekly intervals and sera were taken biweekly as well. Titers to injected peptides, as well as to an irrelevant peptide were determined with every serum. Furthermore, titers against the recombinant human A ⁇ protein, and against original peptides were determined respectively. In general sera were analysed by reaction against peptides coupled to Bovine Serum Albumin (BSA) and recombinant full length proteins which were immobilised on ELISA plates. Titers were determined using anti mouse IgG specific antibodies. For detailed results see Figures 15, 16 and 17 respec- tively and Figures 23, 24 and 25 respectively. 2. Results for MV-OOl, MV-003 and MV-004
  • Fig. 10 depicts the characterisation of the monoclonal antibody MV-OOl (internal name 824; IgGl) derived from experiment Alz-5 demonstrating specificity for full length A ⁇ and A ⁇ truncated at position E3.
  • Fig. 11 depicts the characterisation of the monoclonal antibody MV-003 (internal name D129; IgGl) derived from experiment Alz-16 demonstrating specificity for A ⁇ truncated and posttrans- lationally modified at position p(E)3.
  • Fig. 12 depicts the characterisation of the monoclonal antibody MV-004 (internal name B204; IgGl) derived from experiment Alz-15 demonstrating specificity for A ⁇ truncated at position Ell.
  • Table IA mimotopes binding to the parental antibody MV-003
  • binding capacity is coded by the following binding code: 1:X describes the dilution factor of the parental AB.
  • Table IB mimotopes binding to the parental antibody MV-004
  • binding capacity is coded by the following binding code: 1:X describes the dilution factor of the parental AB.
  • Table 1C mimotopes binding to the parental antibody MV-OOl
  • binding capacity is coded by the following binding code: 1:X describes the dilution factor of the parental AB
  • FIGS 13 and 14 show representative examples for binding and inhibition assays used to characterise mimotopes in vitro. Data obtained are summarised in Tables 1 and 2 respectively.
  • MV-003 Mimotopes From the 8 sequences presented 6 sequences inhibit binding of the p ( E) 3-7A ⁇ specific monoclonal antibody in in vitro competition experiments : Additional 2 sequences were identified that do not inhibit binding of monoclonal antibody in in vitro competition experiments but still retain binding capacity to the parental antibody (Table 2A) .
  • MV-004 Mimotopes All the 9 sequences presented inhibit binding of the monoclonal antibody specifically binding the free N-terminus of A ⁇ truncated at position El l in in vitro competition experiments : ( Table 2B ) .
  • MV-O O l Mimotopes From the 71 sequences presented 27 sequences inhibit binding of the monoclonal antibody specifically directed against A ⁇ truncated at position E3 in in vitro competition experiments : Additional 44 sequences were identif ied that do not inhibit binding of monoclonal antibody in in vitro competition experiments but still retain binding capacity to the parental antibody (Table 2C ) .
  • the inhibition capacity is coded by the following code :
  • Weak inhibition means more peptide is required to lower AB binding than with the original epitope ; strong inhibition means s imilar peptide amounts are required for mimotope and original epitope for lowering AB binding .
  • Mimotopes are compared to the original peptide as s tandard .
  • OD at l Oug peptide used in the assay is used to calculate the compet ition capacity compared to original peptide .
  • Mimotopes are compared to the original peptide as standard. OD at lOug peptide used in the assay is used to calculate the competition capacity compared to original peptide.
  • Mimotopes are compared to the original peptide as standard.
  • OD at lOug peptide used in the assay is used to calculate the competition capacity compared to original peptide .
  • alpha-Secretase induced cleavage product desAPPalpha rived from human APP gi: 112927
  • mice Female C57/bl6 mice, 5-6 mice per group, were subcutaneously immunized with 30 ⁇ g peptide coupled to KLH. Control groups were administered original epitope-KLH conjugates respectively. As adjuvant alum was used (always 1 mg per mouse) . The peptides administered were all able to bind to monoclonal antibodies specifically although some of the peptides did not inhibit the binding of the original epitope to its parental antibody in vitro (in an in vitro inhibition assay) . The in vitro ELISA assay to determine the antibody titer was performed with sera of single mice after each vaccination in a two week interval (see Fig. 15 and 16 respectively) .
  • FIG. 15 to 17 show representative examples for assays used to characterise mimotopes in vivo.
  • Fig. 15 shows examples for in vivo characterisations of the immune response elicited by mimotope vaccination by analysing the immune response against injected peptide and an irrelevant peptide, containing an unrelated sequence.
  • the original epitopes and the mimotopes elicit immune responses against the injected peptides but fail to induce a relevant immune response against an unrelated sequence (pl454) .
  • MV-003-mimotopes original epitope p4373 and the mimotopes p4395, p4396, p4397, and p4399 are depicted in Fig. 15A. All vaccines are mounting similar immune responses against their respective mimotopes. Neither original epitope p4373-vaccine treated nor the animals treated with mimotope p4395, p4396, p4397 or p4399- vaccines mount relevant titers against irrelevant peptide pl454 (Hx -25x less than injected peptides) .
  • MV-004-mimotopes original epitope p4372 and the mimotopes p4417, p4418, p4419, and p4420 are depicted in Fig. 15B. All vaccines are mounting similar immune responses against their respective mimotopes. Neither original epitope p4372-vaccine treated nor the animals treated with mimotope p4417, p4418, p4419, and p4420- vaccines mount relevant titers against irrelevant peptide pl454 (20-8Ox less than injected peptides) .
  • MV-001-mimotopes original epitope p4371 and the mimotopes p4381, p4382, and p4390 are depicted in Fig. 15C. All vaccines are mounting similar immune responses against their respective mimotopes. Neither original epitope p4371-vaccine treated nor the animals treated with mimotope p4381, p4382, and p4390 - vaccines mount relevant titers against irrelevant peptide pl454 (>10x less than injected peptides) .
  • Fig. 16 shows examples for in vivo characterisations of the immune response elicited by mimotope vaccination against the respective original epitope of the parental antibody as well as against peptides derived of other forms of truncated species of A ⁇ .
  • MV-003-mimotopes original epitope p4373 and the mimotopes p4395, p4396, p4397, and p4399 are depicted in Fig. 16A.
  • 3/4 Mimotope vaccines indicated mount detectable immune responses against the original epitope p4373.
  • the original epitope p4373-vaccine and 2/4 Mimotope vaccines mount relevant titers against p4371.
  • the mimotopes selected by MV-003, which is specifically binding to p4373 are also inducing a immune reaction cross reacting with the unmodified form of the original epitope.
  • MV-004-mimotopes original epitope p4372 and the mimotopes p4417, p4418, p4419, and p4420 are depicted in Fig. 16B.
  • 3/4 Mimotope vaccines shown mount detectable immune responses against the original epitope p4372.
  • original epitope p4371 and the mimotopes p4381, p4382, and p4390 are depicted in Fig. 16C. All Mimotope vaccines depicted mount detectable immune responses against the original epitope p4371.
  • a similar phenomenon as described for MV-003 derived mimotopes can be detected analysing cross reactivity against the pyroglutamate-modified form as displayed by p4373.
  • the original epitope p4371-vaccine and all Mimotope vaccines mount relevant titers against p4373.
  • the mimotopes selected by MV-OOl, which is specifically binding to p4371 are inducing a immune reaction cross reacting better with the modified form of the original epitope than the original epitope induced immune reaction or the parental antibody.
  • these mimotopes might surprisingly be able to induce but are not necessarily inducing a broader immune reaction than the parental antibody and can be used for a more wide targeting of forms of A ⁇ .
  • Fig. 17 shows examples for in vivo characterisations of the immune response elicited by mimotope vaccination against full length A ⁇ .
  • the mimotopes selected by using MV-OOl and MV-003 induce a cross reaction not only with the truncated or modified short epitopes used to create the antibodies but also induce cross reactivity to full length, non modified forms of A ⁇ as good as the original sequence or even more efficiently than p4371/p4373.
  • MV-002 original epitope as well as for the mimotopes identified, no such cross reactivity can be detected demonstrating a transfer of specificity of the antibody to the free N-Terminus of unmodified A ⁇ ll-40/42.
  • the mimotopes presented in this invention constitute optimised vaccine candidates to target a broad spectrum of naturally occurring forms of the A ⁇ peptides as have been found in the brain of AD patients.
  • the forms include but are not limited to A ⁇ l-40/42, and N- terminally truncated forms like A ⁇ 3-40/42, A ⁇ (pE) 3-40/42 and unmodified A ⁇ ll-40/42 respectively.
  • Fig. 21 depicts the characterisation of the monoclonal antibody MV-002 (internal name A115; IgG2b) derived from experiment Alz-9 demonstrating specificity for full length A ⁇ and A ⁇ fragments truncated at position Ell and H14 and modified at position Ell to pEll.
  • Table 1 mimotopes binding to the parental antibody MV-002
  • binding capacity is coded by the following binding code: 1:X describes the dilution factor of the parental AB. Ac-...indicates ac- etylated AA.
  • Figures 21 and 22 show representative examples for binding and inhibition assays used to characterise mimotopes in vitro. Data obtained are summarised in Tables 1 and 2 respectively.
  • MV-002 Mimotopes From the 47 sequences presented 11 sequences inhibited binding of the monoclonal antibody MV-002 in in vitro competition experiments. Additional 36 sequences were identified that did not inhibit binding of monoclonal antibody in in vitro competition experiments but still retained binding capacity to the parental antibody (Table 2) . Importantly, as described in Figures 23-25, the ability to compete with the original epitope for binding to the parental antibody in vitro was no prerequisite to mount specific immune responses cross reacting with specific peptides in vivo. Thus inhibiting as well as non- inhibiting peptides can be used for inducing immune responses detecting peptides in vivo (for details see: Figures 23-25) which can lead to clearance of amyloid peptides from the brain.
  • the inhibition capacity is coded by the following code :
  • Mimotopes are compared to the original peptide as standard .
  • OD at 5ug peptide used in the assay is used to calculate the competition capacity compared to original peptide .
  • mice Female C57 /bl 6 mice , 5-6 mice per group , were subcutaneously immuni zed with 30 ⁇ g peptide coupled to KLH . Control groups were administered original epitope-KLH conj ugates respectively . As adj uvant alum was used ( always 1 rug per mouse ) . The peptides administered were all able to bind to monoclonal antibodies specifically although some of the peptides did not inhibit the binding of the original epitope to its parental antibody in vitro ( in an in vitro inhibition assay ) . The in vitro ELI SA assay to determine the antibody titer was performed with sera of sin- gle mice after each vaccination in a two week interval (see Fig. 25 and 26 respectively) .
  • Titers were calculated as OD max/2 in all figures shown.
  • the wells of the ELISA plate were coated with mimotope-BSA conjugate and an irrelevant peptide-BSA conjugate (negative control) .
  • the positive control was performed by reaction of the parental antibody with the respective mimotope-BSA conjugate.
  • the detection was performed with anti-mouse IgG.
  • recombinant proteins were immobilised on ELISA plates and sera reacted accordingly.
  • Figures 23, 24 and 25 show representative examples for assays used to characterise rnimo- topes in vivo. The results depicted were derived from peptides active in in vitro inhibition assays like p4670, p4675, p4680, and p4681 and a peptide without inhibition capacity, p4403 respectively.
  • Fig. 23 shows examples for in vivo characterisations of the immune response elicited by mimotope vaccination by analysing the immune response against injected peptide and an irrelevant peptide, containing an unrelated sequence.
  • the epitope p4377 and the mimotopes p4670, p4675, p4680, p4681 and p4403 elicited immune responses against the injected peptides but failed to induce a relevant unspecific immune response against an unrelated sequence (pl454) .
  • Fig. 24 shows examples for in vivo characterisations of the immune response elicited by mimotope vaccination against the respective original epitope of the parental antibody (p4377) as well as against peptides derived from truncated species of A ⁇ (pl323 and p4374)and against sAPP alpha.
  • p4377 and the mimotopes p4670, p4675, p4680, p4681 and p4403 mounted detectable immune responses against the original epitope p4377.
  • a similar phenomenon could be detected analysing cross reactivity against the modified form as displayed by p4374.
  • Fig. 25 shows examples for in vivo characterisations of the immune response elicited by mimotope vaccination against full length A ⁇ .
  • the mimotopes selected by using MV-002 induced a cross reaction not only with the truncated or modified short epitopes used to create the antibodies but also induced cross reactivity to full length, non modified forms of A ⁇ as good as the original sequence or even more efficiently than p4377.
  • the mimotopes presented in this invention constitute optimised, novel vaccine candidates to target a broad spectrum of naturally occurring forms of the A ⁇ peptides as have been found in the brain of AD patients.
  • the forms include but are not limited to A ⁇ l-40/42, and N-terminally truncated forms like A ⁇ 3-40/42, A ⁇ (pE)3-40/42, unmodified A ⁇ ll-40/42, modified A ⁇ p (E) 11-40/42 and A ⁇ l4-40/42 respectively.
  • the mimotopes presented also did not induce a cross reactivity to the neoepitopes present in sAPP alpha after cleavage from APP and thus do not interfere with normal sAPP alpha signalling (see Fig. 24 for details) .
  • Table 4 further examples of the immune response elicited by mimotope vaccination against full length A ⁇ by using MV-002 derived mimotopes are described. All peptides listed in table 4 mount specific immune reactions against full length and/or truncated and modified forms of A ⁇ or fragments thereof.
  • Example 9 In vivo characterisation of mimotopes for the efficacy to reduce AD like disease in transgenic animals
  • the Tg2576 AD mouse model was used to study the preclinical efficacy of the mimotope vaccines.
  • This transgenic line is expressing human APP carrying the Swedish double mutation at aa position 670/671 under the control of a hamster prion protein (PrP) promoter which results in overexpression of the protein.
  • PrP hamster prion protein
  • the Tg2576 model recapitulates various hallmarks of AD pathology including disease-specific amyloid plaque deposition and astrocytosis. As all other AD model systems available to date, it does not reflect all cardinal neuropathological features of AD.
  • mice were s.c. injected 6 times at monthly intervals with peptide-KLH conjugates adsorbed to ALUM (adjuvant: aluminium hydroxide) or PBS adsorbed to ALUM (referred to as PBS or control) alone.
  • ALUM adjuvant: aluminium hydroxide
  • PBS adsorbed to ALUM
  • animals were sacrificed, their brains harvested and analyzed for their A ⁇ load (AD-like pathology) .
  • the mice were sacrificed under deep anaesthesia.
  • the brain was isolated, fixed in 4%PFA and dehydrated by graded Ethanol series followed by incubation in Xylene and paraffin embedding. Each paraffin-embedded brain was sectioned at 7 ⁇ M using a slicing microtome and sections were mounted on glass slides.
  • mAb 3A5 (specific for A ⁇ 40/42) .
  • Mimotope treated animals were compared to control animals. All animals have been sacrificed at an age of 13,5-14 months. For this analysis 3 slides/animal covering the cortex and hippocampus were selected, stained with mAb 3A5 and subsequently documented using the Mirax-system
  • a similar picture can be detected for the group of MV003 derived mimotopes.
  • the example of p4395 is depicted.
  • an analysis of the area occupied by amyloid plaques following peptide-conjugate vaccination has been performed.
  • the control group showed an average occupation of 0,35% as compared to 0,21% for the mimotope treated animals respectively. This corresponds to a reduction following mimotope treatment of 38% in group 2 (see Fig. 19) .
  • this set of data clearly indicates a beneficial effect of mimotope vaccine treatment on AD like pathology in transgenic animals .
  • Example 10 In vivo characterisation of mimotopes for the efficacy to reduce PD like disease in transgenic animals (proof of concept analysis)
  • the double transgenic mouse model (mThyl-APP751 (line TASD41) crossed with mThyl-wt human a-syn (Line TASD 61) was used to study the preclinical efficacy of AD mimotope vaccines to reduce PD like disease.
  • the model recapitulates various hallmarks of AD and PD pathology including disease-specific amyloid plaque deposition and astrocytosis as well as synuclein aggregation and cell loss.
  • mice were s.c. injected 6 times at monthly intervals with peptide-KLH conjugates adsorbed to ALUM (adjuvant: aluminium hydroxide) or PBS adsorbed to ALUM (referred to as PBS or control) alone.
  • ALUM adjuvant: aluminium hydroxide
  • PBS adjuvant: aluminium hydroxide
  • animals were sacrificed following guidelines for the humane treatment of animals. Subsequently, the brain was isolated, fixed and sectioned at 40 ⁇ M using a vibratome and sections were stored at -2O 0 C in cryoprotective medium. Sections were immunostained with antibodies against ⁇ -synuclein and NeuN (neuronal marker) and imaged with the laser confocal microscope. Digital images were analyzed with the ImageQuant program to assess numbers of ⁇ -synuclein aggregates and neurons. Mimotope treated animals were compared to control animals. Results depict an exemplary set of data for a mimotope described in this invention
  • mice treated with an AD mimotope showed levels of NeuN positive neurons, which were comparable to controls.

Abstract

The present invention relates to a compound comprising a peptide for treating, preventing and/or ameliorating motor symptoms of Parkinson's disease, said peptide having a binding capacity to an antibody which is specific for an epitope of the amyloid-beta-peptide (Aβ).

Description

Compounds for treating symptoms associated with Parkinson's disease
The present invention relates to methods and means for preventing, ameliorating and treat symptoms associated with Parkinson's disease.
Alzheimer's disease (AD) and Parkinson's Disease (PD) are the most common causes of dementia and movement disorders in humans. While AD is characterized by the accumulation of amyloid- beta protein (forming so called Aβ plaques) which is derived from amyloid precursor protein (APP) , PD patients are developing pathologic accumulation of alpha-Synuclein (a-Syn, aSyn; forming so called Lewy Bodies) . Both of these molecules are considered to be the major disease causing agents for these neurodegenerative disorders. Both diseases, AD and PD, are associated with degeneration of neurons and synaptic connections, deficiency of specific neurotransmitters, and abnormal accumulation of mis- folded proteins, whose non pathogenic paternal proteins play important roles in normal central nervous system functions.
Recently, a novel form of dementia associated with movement disorders but clinical symptoms differing from those of AD, vascular dementia or idiopathic parkinsonism has been defined clinically. This novel syndrome has been defined as dementia with Lewy bodies or Parkinson's with dementia (DLB/PDD) . DLB/PDD is amounting to up to 25% of all dementia cases and has to be considered as second most prominent form of dementia in the elderly. The disease is characterized by the formation of widespread Lewy body pathology associated with extensive amyloid deposition. This presence of widespread Lewy bodies differentiates the DLB/PDD cases from all other types of dementia as well as from other movement disorders. The neurological assessment of DLB/PDD shows prominent abnormalities in attention, in executive functions, in memory as well as behavioural and motoric alterations .
It is currently believed that aSyn and Aβ have distinct, as well as convergent, pathogenic effects on the nervous system. Synucleins are believed to affect motoric function more severely than cognitive function, whereas amyloid β peptides are described to have opposite effects. In addition, aSYN and Aβ could interact more directly by engaging synergistic neurodegenerative pathways. It has been recently shown that different pathologic molecules including Aβ, Tau as well as aSyn can mutually exacerbate toxic effects in preclinical disease models and indicate an important function of Aβ in different neurodegenerative conditions. In a recent transgenic animal model for DLB/PDD it has been shown that coexpression of both molecules, haSYN and hAPP, in mice leads to the development of cognitive and motor alterations accompanied by loss of cholinergic neurons and reduction in synaptic vesicles, formation of extensive amyloid plaques, and haSYN-immunoreactive intraneuronal fibrillar inclusions. All of these features are also found in the DLB/PDD syndrome.
Current therapies of symptoms of Parkinson's disease involve the administration of dopaminergic agents to patients suffering from said disease. Dopaminergic agents are believed to reduce the symptoms of Parkinson's disease because it is believed that these symptoms are caused by the deprivation of dopamine in the brain. The insufficiency of dopamine in the brain may therefore be compensated by administering to the patient dopaminergic agents, such as dopamine agonists or dopamine precursors, e.g. levodopa. There is no established cure for Parkinson's disease, which means that the symptoms worsen, necessitating an increase in daily dosage of the medicament as the disease progresses. Furthermore, the chronic use of increased dosages of levodopa leads to the development of motor complications, such as wearing off and involuntary movements (dyskinesia) .
The symptoms of motor dysfunction can be improved by levodopa treatment especially combined with other compounds that improve its efficacy.
One of the major disadvantages of the administration of dopaminergic agents is that these agents have to be administered at regular intervals. Furthermore these agents lead only to an increase of dopaminergeic agents in the patient without removing the cause of the symptoms of Parkinson's disease, namely a-Syn plaques .
It is an object of the present invention to provide means for treating symptoms of Parkinson's disease sustainably by reducing the amount of a-Syn deposits.
The present invention relates to a compound comprising a peptide for treating and/or ameliorating motor symptoms of Parkinson's disease, said peptide having a binding capacity to an antibody which is specific for an epitope of the amyloid-beta- peptide (Aβ) .
It surprisingly turned out that compounds capable to induce antibodies directed to the amyloid-beta-peptide and, hence, employable to treat beta-amyloidoses such as Alzheimer's disease, can be used to treat and ameliorate the symptoms of Parkinson's disease, in particular the motor symptoms of Parkinson's disease. The antibodies formed by the administration of said compounds reduce surprisingly the amount of a-Syn deposits.
"Motor symptoms", as used herein, refers to those symptoms of the Parkinson's disease which are described in the EMEA Guideline on Clinical Investigation of Medicinal Products in the Treatment of Parkinson's Disease (CPMP/EWP/563/95 Rev.l) that affect the motor behaviour of a patient suffering from said disease and affects autonomic functions of a patient as well. These symptoms include but are not limited to the core symptoms resting tremor, bradykinesia, rigidity, postural instability as well as stooped posture, dystonia, fatigue, impaired fine motor dexterity and motor coordination, impaired gross motor coordination, poverty of movement (decreased arm swing), akathisia, speech problems, such as softness of voice or slurred speech caused by lack of muscle control, loss of facial expression, or "masking", micrographia, difficulty swallowing, sexual dysfunction, drooling.
As used herein, the term "epitope" refers to an immunogenic region of an antigen which is recognized by a particular antibody molecule. An antigen may possess one or more epitopes, each capable of binding an antibody that recognizes the particular epitope .
The term "peptide having a binding capacity to an antibody which is specific for an epitope of the amyloid-beta-peptide" means that said peptide can be bound to an amyloid-beta peptide specific antibody which has been produced by the administration of amyloid-beta peptide or fragments thereof to a mammal. Said peptide having said binding capacity is able to induce the formation of amyloid-beta peptide specific antibodies in a mammal. The latter antibodies bind consequently to the compound of the present invention as well as to the amyloid-beta peptide.
According to a preferred embodiment of the present invention said epitope of the amyloid-beta-peptide is selected from the group consisting of DAEFRH, EFRHDSGY, pEFRHDSGY, EVHHQKL, HQKLVF and HQKLVFFAED.
It is particularly preferred to use compounds of the present invention which are able to bind to antibodies directed to/specific for the aforementioned naturally occurring epitopes of the amyloid-beta-peptide. Consequently the compound according to the present invention may comprise a peptide having one of said amino acid sequences.
In another embodiment of the present invention the compound of the present invention does preferably not comprise a peptide having the amino acid sequence DAEFRH, EFRHDSGY, pEFRHDSGY, EVHHQKL, HQKLVF and HQKLVFFAED, but, however, also binds to amyloid-beta-specific antibodies.
For identifying such antibody-inducing peptides phage libraries and peptide libraries can be used. Of course it is also possible to identify such peptides by using means of combinatorial chemistry. All of these methods involve the step of contacting a peptide of a pool of peptides with an amyloid-beta peptide specific antibody. The peptides of the pool binding to said antibody can be isolated and sequenced, if the amino acid sequence of the respective peptide is unknown.
In the following peptides are listed which are able to induce the formation of amyloid-beta antibodies in a mammal. These peptides can also be used for reducing symptoms of Parkinson' s disease .
According to a preferred embodiment of the present invention the peptide comprises the amino acid sequence
X1X2X3X4X5X6X7, (Formula I)
wherein Xi is G or an amino acid with a hydroxy group or a negatively charged amino acid, preferably glycine (G) , glutamic acid (E) , tyrosine (Y) , serine (S) or aspartic acid (D) ,
X2 is a hydrophobic amino acid or a positively charged amino acid, preferably asparagine (N), isoleucine (I), leucine (L), valine (V) , lysine (K) , tryptophane (W) , arginine (R) , tyrosine (Y) , phenylalanine (F) or alanine (A) ,
X3 is a negatively charged amino acid, preferably aspartic acid (D) or glutamic acid (E),
X4 is an aromatic amino acid or a hydrophobic amino acid or leucine (L), preferably tyrosine (Y), phenylalanine (F) or leucine (L) ,
X5 is histidine (H) , lysine (K) , tyrosine (Y) , phenylalanine (F) or arginine (R) , preferably histidine (H) , phenylalanine (F) or arginine (R) , and
Xg is not present or serine (S) , threonine (T) , asparagine (N) , glutamine (Q) , aspartic acid (D) , glutamic acid (E) , arginine (R), isoleucine (I), lysine (K), tyrosine (Y), or glycine (G) , preferably threonine (T) , asparagine (N) , aspartic acid (D), arginine (R), isoleucine (I) or glycine (G),
X7 is not present or any amino acid, preferably proline (P), tyrosine (Y) , threonine (T) , glutamine (Q) , alanine (A) , histidine (H) or serine (S), preferably EIDYHR, ELDYHR, EVDYHR, DIDYHR, DLDYHR, DVDYHR, DI-DYRR, DLDYRR, DVDYRR, DKELRI, DWELRI, YREFFI, YREFRI, YAEFRG, EAEFRG, DYEFRG, ELEFRG, DRELRI, DKELKI, DRELKI, GREFRN, EYEFRG, DWEFRDA, SWEFRT, DKELR, SFEFRG, DAEFRWP, DNEFRSP, GSEFRDY, GAEFRFT, SAEFRTQ, SAEFRAT, SWEFRNP, SWEFRLY, SWELRQA, SVEFRYH, SYEFRHH, SQEFRTP, SSEFRVS, DWEFRD, DAELRY, DWELRQ, SLEFRF, GPEFRW, GKEFRT, AYEFRH, DKE(NIe)R, DKE(Nva)R or DKE(Cha)R.
According to a further embodiment of the present invention said peptide comprises the amino acid sequence
XlRX2DX3(X4)n(X5)m(X6)o, (Formula II),
wherein X1 is isoleucine (I) or valine (V),
X2 is tryptophan (W) or tyrosine (Y) ,
X3 is threonine (T) , valine (V) , alanine (A) , methionine (M) , glutamine (Q) or glycine (G) ,
X4 is proline (P) , alanine (A) , tyrosine (Y) , serine (S) , cysteine (C) or glycine (G) ,
X5 is proline (P), leucine (L), glycine (G) or cysteine (C),
XQ is cysteine (C) , n, m and o are, independently, 0 or 1, preferably IRWDTP(C), VRWDVYP(C), IRYDAPL(C), IRYDMAG(C), IRWDTSL(C), IRWDQP(C), IRWDG(C) or IRWDGG(C) .
The peptide of the compound of the present invention may comprise the amino acid sequence
EX1WHX2X3 (X4)n(X5)in (Formula III), wherein Xi is valine (V) , arginine (R) or leucine (L) ,
X2 is arginine (R) or glutamic acid (E) ,
X3 is alanine (A) , histidine (H) , lysine (K) , leucine (L) , tyrosine (Y) or glycine (G) ,
X4 is proline (P) , histidine (H) , phenylalanine (F) or glutamine (Q) or Cysteine
X5 is cysteine (C) , n and m are, independently, 0 or 1, preferably EVWHRHQ(C), ERWHEKH(C), EVWHRLQ(C), ELWHRYP(C), ELWHRAF(C), ELWHRA(C), EVWHRG(C), EVWHRH(C) and ERWHEK (C) , preferably EVWHRHQ(C), ERWHEKH(C), EVWHRLQ(C), ELWHRYP(C) or EL- WHRAF(C) .
According to a particularly preferred embodiment of the present invention the peptide comprises the amino acid sequence QDFRHY(C), SEFKHG(C), TSFRHG(C), TSVFRH(C), TPFRHT(C), SQFRHY(C), LMFRHN(C), SAFRHH(C), LPFRHG(C), SHFRHG(C), ILFRHG(C), QFKHDL(C), NWFPHP(C), EEFKYS(C), NELRHST(C), GEMRHQP(C), DTYFPRS(C), VELRHSR(C), YSMRHDA(C), AANYFPR(C), SPNQFRH(C), SSSFFPR(C), EDWFFWH(C), SAGSFRH(C), QVMRHHA(C), SEFSHSS(C), QPNLFYH(C), ELFKHHL(C), TLHEFRH(C), ATFRHSP(C), AP- MYFPH(C), TYFSHSL(C), HEPLFSH(C), SLMRHSS(C), EFLRHTL(C), ATPLFRH(C), QELKRYY(C), THTDFRH(C), LHIPFRH(C), NELFKHF(C), SQYFPRP(C), DEHPFRH(C), MLPFRHG(C), SAMRHSL(C), TPLMFWH(C), LQFKHST(C), ATFRHST(C), TGLMFKH(C), AEFSHWH(C), QSEFKHW(C), AEFMHSV(C), ADHDFRH(C), DGLLFKH(C), IGFRHDS(C), SNSEFRR(C), SELRHST(C), THMEFRR(C), EELRHSV(C), QLFKHSP(C), YEFRHAQ(C), SNFRHSV(C), APIQFRH(C), AYFPHTS(C), NSSELRH(C), TEFRHKA(C), TSTEMWH(C), SQSYFKH(C), (C)SEFKH, SEFKH(C), (C)HEFRH or HEFRH(C) .
According to another preferred embodiment of the present invention the peptide comprises the amino acid sequence
(Xl)mGX2X3X4FX5X6(X7)n (Formula IV),
wherein Xi is serine (S) , alanine (A) or cysteine (c) ,
X2 is serine (S) , threonine (T) , glutamic acid (E) , aspartic acid (D), glutamine (Q) or methionine (M),
X3 is isoleucine (I), tyrosine (Y), methionine (M) or leucine (L) , X4 is leucine (L) , arginine (R) , glutamine (Q) , tryptophan (W), valine (V), histidine (H), tyrosine (Y), isoleucine (I), lysine (K) methionine (M) or phenylalanine (F) ,
X5 is alanine (A), phenylalanine (F) histidine (H) , aspar- agine (N) , arginine (R) , glutamic acid (E isoleucine (I ) , glutamine (Q) , aspartic acid (D) , proline P) or tryptophane (W), glycine (G)
Xg is any amino acid residue, X7 is cysteine (C) , m and n are, independently, 0 or 1, preferably SGEYVFH(C), SGQLKFP(C), SGQIWFR(C),' SGEIHFN(C; GQIWFIS(C), GQIIFQS(C), GQIRFDH(C), GEMWFAL(C), GELQFPP(C),
GELWFP(C), GEMQFFI(C) GELYFRA(C), GEIRFAL(C), GMIVFPH(C), GEIWFEG(C), GDLKFPL(C . GQILFPV(C) GELFFPK(C) , GQIMFPR(C) , GSLFFWP(C) GEILFGM(C) , GQLKFPF(C) GTIFFRD(C) , GQIKFAQ(C) , GTLIFHH(C) GEIRFGS (C) . GQIQFPL(C) GEIKFDH(C) , GEIQFGA(C) , GELFFEK(C) GEIRFEL(C) . GEIYFER(C) SGEIYFER(C) AGEIYFER(C) or (C)GEIYFER.
According to a further preferred embodiment of the present invention the peptide comprises the amino acid sequence
(Xl)mHX2X3X4X5FX6(X7)n [ Formula V) ,
wherein Xi is serine (S) , threonine (T) or cysteine (C) ,
X2 is glutamine (Q) , threonine (T) or methionine (M) ,
X3 is lysine (K) or arginine (R) ,
X4 is leucine (L) , methionine (M) ,
X5 is tryptophane (W), tyrosine (Y), phenylalanine (F) or isoleucine (I) ,
Xβ is asparagine (N) , glutamic acid (E) , alanine (A) or cysteine (C) ,
X7 is cysteine (C) , n and m are, independently, 0 or 1 , preferably SHTRLYF(C), HMRLFFN(C), SHQRLWF(C), HQKMIFA(C), HMRMYFE(C), THQRLWF(C) or HQKMIF(C) .
According to a preferred embodiment of the present invention the peptide comprises the amino acid sequence AIPLFVM(C), KLPLFVM(C), QLPLFVL(C) or NDAKIVF (C) .
The compound according to the present invention is preferably a polypeptide/peptide and comprises 4 to 30 amino acid resi- dues, preferably 5 to 25 amino acid residues, more preferably 5 to 20 amino acid residues.
The compound of the present invention may also be part of a polypeptide comprising 4 to 30 amino acid residues.
The peptides exhibiting an affinity to amyloid-beta antibodies may be considered as mimotopes. According to the present invention the term "mimotope" refers to a molecule which has a conformation that has a topology eguivalent to the epitope of which it is a mimic. The mimotope binds to the same antigen- binding region of an antibody which binds immunospecifically to a desired antigen. The mimotope will elicit an immunological response in a host that is reactive to the antigen to which it is a mimic. The mimotope may also act as a competitor for the epitope of which it is a mimic in in vitro inhibition assays (e.g. ELISA inhibition assays) which involve the epitope and an antibody binding to said epitope. However, a mimotope of the present invention may not necessarily prevent or compete with the binding of the epitope of which it is a mimic in an in vitro inhibition assay although it is capable to induce a specific immune response when administered to a mammal. The compounds of the present invention comprising such mimotopes (also those listed above) have the advantage to avoid the formation of autoreactive T-cells, since the peptides of the compounds have an amino acid sequence which varies from those of naturally occurring amyloid- beta peptide.
The mimotopes/peptides of the present invention can be synthetically produced by chemical synthesis methods which are well known in the art, either as an isolated peptide or as a part of another peptide or polypeptide. Alternatively, the peptide mimotope can be produced in a microorganism which produces the peptide mimotope which is then isolated and if desired, further purified. The peptide mimotope can be produced in microorganisms such as bacteria, yeast or fungi, in eukaryote cells such as a mammalian or an insect cell, or in a recombinant virus vector such as adenovirus, poxvirus, herpesvirus, Simliki forest virus, baculovirus, bacteriophage, sindbis virus or sendai virus. Suitable bacteria for producing the peptide mimotope include E.coli, B.subtilis or any other bacterium that is capable of expressing peptides such as the peptide mimotope. Suitable yeast types for expressing the peptide mimotope include Saccharomyces cere- visiae, Schizosaccharomyces pombe, Candida, Pichia pastoris or any other yeast capable of expressing peptides. Corresponding methods are well known in the art. Also methods for isolating and purifying recombinantly produced peptides are well known in the art and include e.g. as gel filtration, affinity chromatography, ion exchange chromatography etc..
To facilitate isolation of the peptide mimotope, a fusion polypeptide may be made wherein the peptide mimotope is transla- tionally fused (covalently linked) to a heterologous polypeptide which enables isolation by affinity chromatography. Typical heterologous polypeptides are His-Tag (e.g. His6; 6 histidine residues), GST-Tag (Glutathione-S-transferase) etc.. The fusion polypeptide facilitates not only the purification of the mimo- topes but can also prevent the mimotope polypeptide from being degraded during purification. If it is desired to remove the heterologous polypeptide after purification the fusion polypeptide may comprise a cleavage site at the junction between the peptide mimotope and the heterologous polypeptide. The cleavage site consists of an amino acid sequence that is cleaved with an enzyme specific for the amino acid sequence at the site (e.g. proteases) .
The mimotopes of the present invention may also be modified at or nearby their N- and/or C-termini so that at said positions a cysteine residue is bound thereto. In a preferred embodiment terminally positioned (located at the N- and C-termini of the peptide) cysteine residues are used to cyclize the peptides through a disulfide bond.
The mimotopes of the present invention may also be used in various assays and kits, in particular in immunological assays and kits. Therefore, it is particularly preferred that the mimotope may be part of another peptide or polypeptide, particularly an enzyme which is used as a reporter in immunological assays. Such reporter enzymes include e.g. alkaline phosphatase or horseradish peroxidase.
The mimotopes according to the present invention preferably are antigenic polypeptides which in their amino acid sequence vary from the amino acid sequence of Aβ or of fragments of Aβ . In this respect, the inventive mimotopes may not only comprise amino acid substitutions of one or more naturally occurring amino acid residues but also of one or more non-natural amino acids (i.e. not from the 20 "classical" amino acids) or they may be completely assembled of such non-natural amino acids. Moreover, the inventive antigens which induce antibodies directed and binding to Aβl-40/42, AβpE3-40/42, Aβ3-40/42, Aβll-40/42, AβpEll-40/42 and Aβl4-40/42 (and other N-terminally truncated forms of Aβ starting from amino acid positions 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13) may be assembled of D- or L- amino acids or of combinations of DL- amino acids and, optionally, they may have been changed by further modifications, ring closures or derivatizations . Suitable antibody-inducing antigens may be provided from commercially available peptide libraries. Preferably, these peptides are at least 7 amino acids, and preferred lengths may be up to 16, preferably up to 14 or 20 amino acids (e.g. 5 to 16 amino acid residues) . According to the invention, however, also longer peptides may very well be employed as antibody- inducing antigens. Furthermore the mimotopes of the present invention may also be part of a polypeptide and consequently comprising at their N- and/or C-terminus at least one further amino acid residue.
For preparing the mimotopes of the present invention (i.e. the antibody-inducing antigens disclosed herein) , of course also phage libraries, peptide libraries are suitable, for instance produced by means of combinatorial chemistry or obtained by means of high throughput screening techniques for the most varying structures (Display: A Laboratory Manual by Carlos F. Barbas (Editor), et al.; Willats WG Phage display: practicalities and prospects. Plant MoI. Biol. 2002 Dec; 50 ( 6) : 837-54) .
Furthermore, according to the invention also anti-Aβl-40/42- , -AβpE3-40/42-, -Aβ3-40/42-, -Aβll-40/42- AβpEll-40/42- and Aβl4-40/42-antibody-inducing antigens based on nucleic acids ("aptamers") may be employed, and these, too, may be found with the most varying (oligonucleotide) libraries (e.g. with 2-180 nucleic acid residues) (e.g. Burgstaller et al., Curr. Opin. Drug Discov. Dev. 5(5) (2002), 690-700; Famulok et al., Ace. Chem. Res. 33 (2000), 591-599; Mayer et al., PNAS 98 (2001), 4961-4965, etc.) . In antibody-inducing antigens based on nucleic acids, the nucleic acid backbone can be provided e.g. by the natural phosphor-diester compounds, or also by phosphorotioates or combinations or chemical variations (e.g. as PNA), wherein as bases, according to the invention primarily U, T, A, C, G, H and mC can be employed. The 2 ' -residues of the nucleotides which can be used according to the present invention preferably are H, OH, F, Cl, NH2, 0-methyl, O-ethyl, O-propyl or O-butyl, wherein the nucleic acids may also be differently modified, i.e. for instance with protective groups, as they are commonly employed in oligonucleotide synthesis. Thus, aptamer-based antibody-inducing antigens are also preferred antibody-inducing antigens within the scope of the present invention.
According to a preferred embodiment of the present invention the compound is coupled to a pharmaceutically acceptable carrier, preferably KLH (Keyhole Limpet Hemocyanin) , tetanus toxoid, albumin-binding protein, bovine serum albumin, a den- drimer (MAP; Biol. Chem. 358: 581), peptide linkers (or flanking regions) as well as the adjuvant substances described in Singh et al., Nat. Biotech. 17 (1999), 1075-1081 (in particular those in Table 1 of that document), and O'Hagan et al., Nature Reviews, Drug Discovery 2 (9) (2003), 727-735 (in particular the endogenous immuno-potentiating compounds and delivery systems described therein), or mixtures thereof. The conjugation chemistry (e.g. via heterobifunctional compounds such as GMBS and of course also others as described in "Bioconjugate Techniques", Greg T. Hermanson) in this context can be selected from reactions known to the skilled man in the art. Moreover, the vaccine composition may be formulated with an adjuvant, preferably a low soluble aluminium composition, in particular aluminium hydroxide. Of course, also adjuvants like MF59 aluminium phosphate, calcium phosphate, cytokines (e.g., IL-2, IL-12, GM-CSF), saponins (e.g., QS21), MDP derivatives, CpG oligos, LPS, MPL, poly- phosphazenes, emulsions (e.g., Freund's, SAF), liposomes, viro- somes, iscoms, cochleates, PLG microparticles, poloxamer particles, virus-like particles, heat-labile enterotoxin (LT) , cholera toxin (CT), mutant toxins (e.g., LTK63 and LTR72), microparticles and/or polymerized liposomes may be used.
The compound of the present invention is preferably bound to the carrier or adjuvant via a linker, which is selected from the group consisting of NHS-poly (ethylene oxide) (PEO) (e.g. NHS- PEO4-maleimide) .
A vaccine which comprises the present compound (mimotope, peptide) and the pharmaceutically acceptable carrier may be administered by any suitable mode of application, e.g. i.d., i.v., i.p., i.m., intranasally, orally, subcutaneously, etc. and in any suitable delivery device (O'Hagan et al . , Nature Reviews, Drug Discovery 2 (9), (2003), 727-735). The compound of the present invention is preferably formulated for intravenous, subcutaneous, intradermal or intramuscular administration (see e.g. "Handbook of Pharmaceutical Manufacturing Formulations", Sar- faraz Niazi, CRC Press Inc, 2004) .
The medicament (vaccine) according to the present invention contains the compound according to the invention in an amount of from 0.1 ng to 10 mg, preferably 10 ng to 1 mg, in particular 100 ng to 100 μg, or, alternatively, e.g. 100 fmol to 10 μmol, preferably 10 pmol to 1 μmol, in particular 100 pmol to 100 nrαol. Typically, the vaccine may also contain auxiliary substances, e.g. buffers, stabilizers etc.
According to a preferred embodiment of the present invention the motor symptoms of Parkinson's disease are selected from the group consisting of resting tremor, Bradykinesia, rigidity, postural instability, stooped posture, dystonia, fatigue, impaired fine motor dexterity and motor coordination, impaired gross motor coordination, poverty of movement (decreased arm swing) , akathisia, speech problems, loss of facial expression, micro- graphia, difficulty swallowing, sexual dysfunction and drooling.
Another aspect of the present invention relates to the use of a compound according to the present invention for the manufacture of a medicament for treating, preventing and/or ameliorating motor symptoms of Parkinson's disease.
Yet another aspect of the present invention relates to a method for treating and/or ameliorating symptoms, in particular motor symptoms, of Parkinson's disease.
The present invention is further illustrated in the following figures and examples, however, without being restricted thereto.
Fig. 1 shows the individualised peptide members of library 4 used for the present screening process.
Fig. 2 shows an inhibition assay with mimotopes for DAEFRH.
Fig. 3 shows another inhibition assay with other mimotopes for DAEFRH.
Figs. 4 and 5 describe the results of inhibition assays performed with mimotope peptides according to the present invention. Figs. 6 to 9 show the results of inhibition assays performed with mimotope peptides 4011-4018, 4019-4025, 4031-4038 and 4061- 4064, respectively.
Fig. 10 shows binding of monoclonal antibody MV-001 to specific peptides and recombinant proteins;
Fig. 11 shows binding of monoclonal antibody MV-003 to specific peptides and recombinant proteins;
Fig. 12 shows binding of monoclonal antibody MV-004 to specific peptides and recombinant proteins;
Fig. 13 shows typical binding assays with mimotopes for β- amyloid and N-terminally truncated and/or posttranslationally modified β-amyloid fragments;
Fig. 14 shows typical inhibition assays with mimotopes for β-amyloid and N-terminally truncated and/or posttranslationally modified β-amyloid fragments;
Fig. 15 shows examples for in vivo characterisations of the immune response elicited by mimotope vaccination (injected pep- tide/irrelevant peptide) ;
Fig. 16 shows examples for in vivo characterisation of the immune response elicited by mimotope vaccination against Amyloid Beta fragments;
Fig. 17 shows examples for in vivo characterisation of the immune response elicited by mimotope vaccination against full length
Fig. 18 shows areas occupied by amyloid plaques. Tg2576 were injected 6 times with mimotope vaccines adjuvanted with aluminium hydroxide (ALUM) by s.c. inoculation at monthly intervals. Control mice received PBS-ALUM only. Area occupied by amyloid plaques shown as percent of the control group. GrI...control group; Gr2... received p4381; Gr3... received p4390; Gr4... received p4715
Fig. 19 shows areas occupied by amyloid plaques. Tg2576 were injected 6 times with AFFITOPE vaccines adjuvanted with aluminium hydroxide (ALUM) by s.c. inoculation at monthly intervals. Control mice received PBS-ALUM only. Area occupied by amyloid plaques shown as percent of the control group. GrI...control group; Gr2... received p4395.
Fig. 20 shows binding of monoclonal antibody MV-002 to specific peptides and recombinant proteins.
Fig. 21 shows typical binding assays with mimotopes for β- amyloid and N-terminally truncated and/or posttranslationally modified β-amyloid fragments.
Fig. 22 shows typical inhibition assays with mimotopes for β-amyloid and N-terminally truncated and/or posttranslationally modified β-amyloid fragments.
Fig. 23 shows examples for in vivo characterisations of the immune response elicited by mimotope vaccination (injected pep- tide/irrelevant peptide) .
Fig. 24 shows examples for in vivo characterisation of the immune response elicited by mimotope vaccination against Amyloid Beta fragments and sAPP-alpha.
Fig. 25 shows examples for in vivo characterisation of the immune response elicited by mimotope vaccination against full length Aβ40/42.
Fig. 26 shows areas occupied by amyloid plaques. Tg2576 were injected 6 times with mimotope vaccines adjuvanted with aluminium hydroxide (ALUM) by s.c. inoculation at monthly intervals. Control mice received PBS-ALUM only. Area occupied by amyloid plaques shown as percent of the control group. GrI...control group; Gr2... received p4675.
Fig. 27 shows a-synuclein positive inclusions. A.. Control treated animal; B.. AD mimotope treated animal; A and B display cortical sections stained for a-synuclein. Positive staining shows neuronal cells including pyramidal and non-pyramidal neurons. Arrows indicate two typical examples for inclusions in A and B. C. Number of inclusions in cortex and hippocampus (indicated as cortex) .
Fig. 28 shows neuronal density. Pictures display cortical sections stained for NeuN. positive staining shows neuronal cells including pyramidal and non-pyramidal neurons. A., indicates a control treated animal; B.. Shows an AD mimotope treated animal respectively. C and D.. shows the the number of NeuN positive neurons in the cortex and hippocampus.
EXAMPLES :
Exampl e 1 : Genera ti on of monocl onal an tibodies (mAb) to detect AB 42-derived peptide species wi th free N-terminus (free as- parti c a cid a t the N-terminus) Mice are vaccinated with the βmer peptide DAEFRH (natural N- terminal Aβ42 sequence) linked to the protein bovine serum albumin BSA (to make use of the hapten-carrier-effect ) , emulsified in CFA (first injection) and IFA (booster injections) . DAEFRH- peptide-specific, antibody-producing hybridomas are detected by ELISA (DAEFRH-peptide-coated ELISA plates) . Peptide SEVKMDAEFRH (natural N-terminally prolonged sequence, APP-derived, containing the Aβ42-derived sequence DAEFRH) is used as negative control peptide: hybridomas recognizing the prolonged peptide are excluded because they do not distinguish between Aβ42-derived peptides with free aspartic acid at the N-terminus and APP- derived peptide DAEFRH without free aspartic acid.
Example 2: Identifying Mimotopes by Inhibition Assay
3.1. Libraries
The peptide libraries employed in inhibition assays (see below) are disclosed in WO 2004/062556.
3.2. Inhibition assay
Figures 2 and 3 describe the results of inhibition assays performed with mimotope peptides included in and obtained from the 5 libraries (as described in WO 2004/062556) . The mimotope peptides compete with the original epitope for recognition by the monoclonal antibody. Original epitope and mimotope peptides contain an additional C at the C-terminus for coupling to a protein carrier (if desired) .
The following peptides are used:
Peptide 1737 DAEFRH
Peptide 3001 DKELRI
Peptide 3002 DWELRI
Peptide 3003 YREFFI
Peptide 3004 YREFRI
Peptide 3005 YAEFRG
Peptide 3006 EAEFRG
Peptide 3007 DYEFRG
Peptide 3008 ELEFRG Peptide 3009 SFEFRG Peptide 3010 DISFRG Peptide 3011 DIGWRG Procedure :
ELISA plates (Nunc Maxisorp) are coated with the original peptide epitope DAEFRH (C-terminally prolonged with C and coupled to bovine serum albumin BSA) at a concentration of 0.1 μg/ml peptide-BSA (100μl/well, 12h, 4°C) . After blocking with PBS/BSA 1% (200μl/well, 12h, 4°C) , the plates are washed 3x times with PBS/Tween. Then, biotinylated monoclonal antibody (1:2000, 50μl/well) and peptides (50μl/well) at 50, 5, 0.5, 0.05, 0.005, and 0.0005 μg/ml are added for 20 min. at 37°C. The plates are washed 3x times with PBS/Tween and are incubated with horseradish peroxidase (HRP) -labeled streptavidin (100μl/well, 30 min, RT) . The plates are washed 5x times with PBS/Tween and are incubated with ABTS + H2O2 (0.1% w/v, 10 to 45 min) and the reaction is stopped with citric acid followed by photometric evaluation (wavelength 405 nm) .
As expected and seen in Fig.2, peptide 1737 DAEFRH can compete with BSA-coupled, plate-bound peptide DAEFRH and thus inhibits recognition by the monoclonal antibody. Furthermore, it is shown that peptide 3003 is not able to inhibit binding of the monoclonal antibody to the original epitope. In contrast, peptides 3001, 3002, 3004, 3005, 3006, and 3007 (to a different extent) block epitope recognition. Whereas peptide 3004 is only inhibitory at a high concentration (50 μg/ml), peptides 3001, 3006, and 3007 are strongly inhibitory with an IC50 of less than 0.5 μg/ml. Peptides 3002 and 3005 are "intermediate" inhibitors with an IC50 of more than 0.5 μg/ml.
As expected and seen in Fig.3, peptide 1737 DAEFRH can successfully compete with BSA-coupled, plate-bound peptide DAEFRH for monoclonal antibody recognition in an additionally performed, independent experiment. Furthermore, it is shown that peptides 3010 and 3011 are not inhibitory at the concentrations tested, whereas peptides 3008 and 3009 are (relatively) weak inhibitors with an IC50 of less than 5 μg/ml.
Table 1 briefly summarizes the inhibitory capacity of mimo- topes included in and obtained from libraries (as described) :
Table 1: Inhibitory capacity of mimotopes:
Peptide 3001 DKELRI strong
Peptide 3002 DWELRI intermediate
Peptide 3003 YREFFI none
Peptide 3004 YREFRI weak
Peptide 3005 YAEFRG intermediate
Peptide 3006 EAEFRG strong
Peptide 3007 DYEFRG strong
Peptide 3008 ELEFRG weak
Peptide 3009 SFEFRG weak
Peptide 3010 DISFRG none
Peptide 3011 DIGWRG none
Exampl e 3 : Inhibition Assay for Additional Mimotopes Scree- nend According to the Present Invention
Inhibition assay
Figures 4 and 5 describe the results of inhibition assays performed with mimotope peptides included in and obtained from the 5 libraries as described in WO 2004/062556. The mimotope peptides compete with the orginal epitope for recognition by the monoclonal antibody. Original epitope and mimotope peptides contain an additional C at the C-terminus (position 7) for coupling to a protein carrier (if desired) .
The following peptides are used:
Peptide 1737 DAEFRH (original epitope + C)
Peptide 1234 KKELRI
Peptide 1235 DRELRI
Peptide 1236 DKELKI
Peptide 1237 DRELKI
Peptide 1238 DKELR Peptide 1239 EYEFRG Peptide 1241 DWEFRDA Peptide 4002 SWEFRT Peptide 4003 GREFRN Peptide 4004 WHWSWR Procedure :
ELISA plates (Nunc Maxisorp) are coated with the original peptide epitope DAEFRH (C-terminally prolonged with C and coupled to bovine serum albumin BSA) at a concentration of 0.1 μg/ml peptide-BSA (100μl/well, 12h, 4°C) . After blocking with PBS/BSA 1% (200μl/well, 12h, 4°C), the plates are washed 3x times with PBS/Tween. Then, biotinylated monoclonal antibody (1:2000, 50μl/well) and peptides (50μl/well) at different concentrations are added for 20 min. at 37°C. The plates are washed 3x times with PBS/Tween and are incubated with horseradish peroxidase (HRP) -labeled streptavidin (100μl/well, 30 min, RT) . The plates are washed 5x times with PBS/Tween and are incubated with ABTS + H2O2 (0.1% w/v, 10 to 45 min) and the reaction is stopped with citric acid followed by photometric evaluation (wavelength 405 nm) .
As expected and seen in Fig.4, peptide 1737 DAEFRH can compete with BSA-coupled, plate-bound peptide DAEFRH and thus inhibits recognition by the monoclonal antibody. Furthermore, it is shown that peptide 4004 is not able to inhibit binding of the monoclonal antibody to the original epitope. In contrast, peptides 4002 and 4003 (to a different extent) block epitope recognition. Whereas peptide 4003 is only inhibitory at a relatively high concentration (10 μg/ml), peptide 4002 is strongly inhibitory with an IC50 of less than 0.4 μg/ml.
As expected and seen in Fig.5, peptide 1737 DAEFRH can successfully compete with BSA-coupled, plate-bound peptide DAEFRH for monoclonal antibody recognition in an additionally performed, independent experiment. Furthermore, it is shown that peptide 1234 is hardly inhibitory at the concentrations tested, whereas peptides 1235, 1236, 1237, 1238, 1239 and 1241 (to a different extent) block epitope recognition. Peptides 1235, 1238 and 1241 are strong inhibitors with an IC50 of less than 0.5 μg/ml, whereas peptides 1236 and 1237 are (relatively) weak inhibitors with an IC50 of more than 5 μg/ml. Peptide 1239 is an intermediate inhibitor with an ICc1Q of more than 0.5 μg/ml.
Table 2 briefly summarizes the inhibitory capacity of mimo- topes included in and obtained from libraries (as described) :
Table 2: Inhibitory capacity of mimotopes:
Peptide 1234 KKELRI none
Peptide 1235 DRELRI strong
Peptide 1236 DKELKI weak
Peptide 1237 DRELKI weak
Peptide 1238 DKELR strong
Peptide 1239 EYEFRG intermediate
Peptide 1241 DWEFRDA strong
Peptide 4002 SWEFRT strong
Peptide 4003 GREFRN weak
Peptide 4004 WHWSWR none
The results presented in Figures 4 and 5 show that in addition to various 6mer peptides (as shown here and before) , 5mer peptides (namely peptide 1238 DKELR) and 7mer peptides (namely peptide 1241 DWEFRDA) may be used as epitopes in a mimotope- based Alzheimer vaccine.
Examp1 e 4 : Inhibition Assay for Mimotopes of the present invention and disclosed in WO 2006/005707 Libraries :
The mimotopes are obtained as described in WO 2006/005707. The following peptides are used for the following assays: Peptide 1737 DAEFRH original epitope Peptide 4011 DAEFRWP 7mer s Peptide 4012 DNEFRSP 7mer s Peptide 4013 GSEFRDY 7mer m Peptide 4014 GAEFRFT 7mer m
Peptide 4015 SAEFRTQ 7mer S
Peptide 4016 SAEFRAT 7mer S
Peptide 4017 SWEFRNP 7mer S
Peptide 4018 SWEFRLY 7mer S
Peptide 4019 SWFRNP βmer -
Peptide 4020 SWELRQA 7mer S
Peptide 4021 SVEFRYH 7mer S
Peptide 4022 SYEFRHH 7mer S
Peptide 4023 SQEFRTP 7mer S
Peptide 4024 SSEFRVS 7mer S
Peptide 4025 DWEFRD 6mer S
Peptide 4031 DAELRY 6mer S
Peptide 4032 DWELRQ 6mer S
Peptide 4033 SLEFRF 6mer S
Peptide 4034 GPEFRW βmer S
Peptide 4035 GKEFRT 6mer S
Peptide 4036 AYEFRH βmer m
Peptide 4037 VPTSALA 7mer -
Peptide 4038 ATYAYWN 7mer
Furthermore, the following 5mer peptides (with non natural amino acids) are used for inhibition assays:
Peptide 4061 DKE(tBuGly)R 5mer
Peptide 4062 DKE(NIe)R 5mer m
Peptide 4063 DKE(Nva)R 5mer m
Peptide 4064 DKE((Cha)R 5mer m
|s: strong inhibition, m: moderate inhibition; -: no inhibi- tion)
Procedure :
ELISA plates (Nunc Maxisorp) are coated with the original peptide epitope DAEFRH (C-terminally prolonged with C and coupled to bovine serum albumin BSA) at a concentration of 0.1 μg/ml peptide-BSA (100μl/well, 12h, 4°C) . After blocking with PBS/BSA 1% (200μl/well, 12h, 4°C), the plates are washed 3x times with PBS/Tween. Then, biotiriylated monoclonal antibody (1:2000, 50μl/well) and peptides (50μl/well) at different concentrations are added for 20 min. at 37°C. The plates are washed 3x times with PBS/Tween and are incubated with horseradish peroxidase (HRP) -labeled streptavidin (100μl/well, 30 min, RT) . The plates are washed 5x times with PBS/Tween and are incubated with ABTS + H2O2 (0.1% w/v, 10 to 45 min) and the reaction is stopped with citric acid followed by photometric evaluation (wavelength 405 ran) .
As expected and seen in Figure 6 (showing peptides 4011- 4018), peptide 1737 DAEFRH can compete with BSA-coupled, plate- bound peptide DAEFRH and thus inhibits recognition by the monoclonal antibody. Furthermore, it is shown that peptides 4012 DNEFRSP, 4013 GSEFRDY, and 4014 GAEFRFT are able to moderately inhibit binding of the monoclonal antibody to the original epitope. In contrast, peptides 4011 DAEFRWP, 4015 SAEFRTQ, 4016 SAEFRAT, 4017 SWEFRNP, and 4018 SWEFRLY (to a different extent) strongly block epitope recognition.
As expected and presented in Figure 7 (showing peptides 4019-4025), peptide 1737 DAEFRH can successfully compete with BSA-coupled, plate-bound peptide DAEFRH for monoclonal antibody recognition in an additionally performed, independent experiment. Furthermore, it is shown that peptide 4019 SWFRNP is not inhibitory at the concentrations tested, whereas peptides 4020 SWELRQA, 4021 SVEFRYH, 4022 SYEFRHH, 4023 SQEFRTP, 4024 SSERFVS and 4025 DWEFRD (to a different extent) block epitope recognition. Peptides 4021, 4022, 4023, 4024 and 4025 are strong inhibitors with an IC50 of less than 0.5 μg/ml, whereas peptide 4020 is an intermediate inhibitor with an IC50 of more than 0.5 μg/ml.
As expected and seen in Figure 8 (peptides 4031-4038) , peptide 1737 DAEFRH can successfully compete with BSA-coupled, plate-bound peptide DAEFRH for monoclonal antibody recognition in a 3rd independent experiment. Furthermore, it is shown that peptides 4037 VPTSALA and 4038 ATYAYWN are not inhibitory at the _ o ^ — concentrations tested, whereas peptides 4031 DAELRY, 4032 DWELRQ, 4033 SLEFRF, 4034 GPEFRW, 4035 GKEFRT and 4036 AYEFRH
(to a different extent) block epitope recognition. Peptides 4031, 4032, 4033, 4034 and 4035 are relatively strong inhibitors with an IC50 of less than 0.5 μg/ml, whereas peptide 4036 is a
(relatively) weak inhibitor with an IC50 of more than 0.5 μg/ml.
In the following Table further examples of the immune response elicited by using AD mimotopes are described. All peptides listed in table 1 mount specific immune reactions against full length Aβ and/or fragments thereof.
Figure imgf000023_0001
Example 5: Inhibition assay with defined 5mer peptides : non- natural amino acids
It has been shown previously that the 5mer peptide 1238 DKELR may be used as epitope in a mimotope-based Alzheimer vaccine (see PCT/EP04/00162) . In the following, amino acids of the original 5mer epitope are replaced by non-natural amino acids: L is replaced by the non-natural amino acids tBuGly, NIe, Nva, or Cha.
As expected and presented in Figure 9 (peptides 4061-4064 DKELR. variants) , peptide 1737 DAEFRH can successfully. compete with BSA-coupled, plate-bound peptide DAEFRH for monoclonal antibody recognition in a 4th independent experiment. Furthermore, it is shown that peptide 4061 DKE(tBuGly)R is not inhibitory at the concentrations tested. Interestingly, peptides 4062 DKE(NIe)R, 4063 DKE ((Nva) R, and 4064 DKE (Cha) R (to a different extent) block epitope recognition. Peptides 4062, 4063, and 4064 are relatively weak inhibitors with an IC50 of more than 0.5 μg/ml.
Example 6: Generation of monoclonal antibodies to specifically detect Si-amyloid and N-terminally truncated and/or post- translationally modified β-amyloid fragments .
Methods
The antibodies used for the mimotope identification according to the following examples detect amino acid sequences derived from human Aβ but do not bind to full length human APP. The sequences detected include EFRHDS (= original epitope aa3-8 of Aβ), p (E) FRHDS (= original epitope of the modified aa3-8 of Aβ), EVHHQK (= original epitope aall-16 of Aβ ) . The antibody may be a monoclonal or polyclonal antibody preparation or any antibody part or derivative thereof, the only prerequisite is that the antibody molecule specifically recognises at least one of the epitopes mentioned above (derived from human Aβ), but does not bind to full length human APP.
The mimotopes are identified and further characterised with such monoclonal antibodies and peptide libraries. Example 6a : Generation of monoclonal antibody MV-OOl
A monoclonal antibody derived from the fusion of experiment Alz-5 was generated: In experiment Alz~5 C57/B16 mice were immunized repeatedly with original Aβ epitope DAEFRHDSGYC coupled to KLH (Keyhole Limpet Hemocyanin) and Alum (Aluminium Hydroxide) as adjuvant. p4371-peptide-specific, antibody-producing hy- bridomas were detected by ELISA (pl253- and p4371-peptide-coated ELISA plates) . Human AB40/42 (recombinant protein) was used as positive control peptide: hybridomas recognizing the recombinant protein immobilised on ELISA plates were included because they are binding both peptide and full length Aβ specifically. P1454 (Human Aβ 33-40) was used as negative control peptide. Furthermore hybridomas were tested against p4373. Only hybridomas with no or limited p4373 binding were used for further antibody development .
The Hybridoma clone (MV-OOl (internal name 824; IgGl) was purified and analysed for specific detection of pl253, p4371, p4373, pl454 and Aβ respectively. MV-001 recognised the injected epitope (pl253) as well as the specific epitope (p4371) and full length Aβ protein (recombinant protein; obtained from Bachem AG, Bubendorf, Switzerland) in ELISA. It however did not detect pl454 in ELISA. Furthermore, the MV-001 antibodies basically failed to detect the peptide p4373 encoding the pyroglutamate version of Aβ3-10 (30 times lower titer than the original epitopes) .
Example 6b: Generation of monoclonal antibody MV-003
A monoclonal antibody derived from the fusion of experiment Alz-16 was generated: In experiment Alz-16 BaIbC mice were immunized repeatedly with the epitope p (E) FRHDSC (p4373) coupled to KLH (Keyhole Limpet Hemocyanin) and Alum (Aluiminium Hydroxide) as adjuvant. p4373-peptide-specific, antibody-producing hybridomas were detected by ELISA (p4373-peptide-coated ELISA plates) . pl253, pl454 and Aβ40/42 were used as negative control peptides. Furthermore, hybridomas were tested against p4371. Only hybridomas with no or limited p4371 binding were used for further antibody development in order to guarantee for pyroglutamate- specificity .
The Hybridoma clone (MV-003 (internal name D129; IgGl) was purified and analysed for specific detection of pl253, p4371, p4373, pl454 and Aβ respectively. MV-003 recognized the injected epitope (p4373) but failed to detect pl454, pl253 or full length Aβ protein (recombinant protein; obtained from Bachem AG, Buben- dorf, Switzerland) in ELISA. Furthermore, the MV-003 antibodies failed to detect the peptide p4371 encoding the normal version of AB3-10 (15 times lower titer than the original epitope) .
Example 6c: Generation of monoclonal antibody MV-004
A monoclonal antibody derived from the fusion of experiment Alz-15 was generated: In experiment Alz-15 BaIbC mice were immunized repeatedly with the epitope EVHHQKC (p4372) coupled to KLH (Keyhole Limpet Hemocyanin) and Alum (Aluiminium Hydroxide) as adjuvant. p4372-peptide-specific, antibody-producing hybridomas were detected by ELISA (p4372-peptide-coated ELISA plates) . P4376, p4378, pl454 and Aβ40/42 were used as negative control peptides. Only hybridomas with no or limited p4376 and p4378 binding were used for further antibody development in order to guarantee for specificity against the free N-Terminus at position aall.
The Hybridoma clone (MV-004 (internal name B204; IgGl) was purified and analysed for specific detection of p4372, p4376, p4378, pl454 and Aβ respectively. MV-004 recognized the injected epitope (p4372) but failed to detect pl454, p4376 and p4378 as well as full length Aβ protein (recombinant protein; obtained from Bachem AG, Bubendorf, Switzerland) in ELISA. The failure to detect p4376, p4378 demonstrates specificity for the free N- terminus at position aall in truncated Aβ .
Example 6d: Generation of monoclonal antibodies to specifically detect β-amyloid and ^-terminally truncated and/or post- translationally modified β-amyloid fragments - monoclonal antibody hW-002
Methods
The antibodies used for the mimotope identification according to the present invention detect amino acid sequences derived from human Aβ but do not bind to full length human APP. The sequences detected include EVHHQKLVFFAED (= original epitope aall- 24 of Aβ) and p (E) VHHQKLVF (p4374 = original epitope aall-19 of Aβ with a pyroglutamate modification at the N-Terminus) . The an- tibody may be a monoclonal or polyclonal antibody preparation or any antibody part or derivative thereof, the only prerequisite is that the antibody molecule specifically recognises at least one of the epitopes mentioned above (derived from human Aβ) , but does not bind to full length human APP.
The mimotopes are identified and further characterised with such monoclonal antibodies and peptide libraries.
A monoclonal antibody derived from the fusion of experiment Alz-9 was generated: C57/B16 mice were immunized repeatedly with original Aβ epitope HQKLVFC coupled to KLH (Keyhole Limpet Hemo- cyanin) and Alum (Aluiminium Hydroxide) as adjuvant. p4377 pep- tide-specific, antibody-producing hybridomas were detected by ELISA (p4377-peptide-coated ELISA plates) . Human Aβ40/42 (recombinant protein) was used as positive control peptide: hybridomas recognizing the recombinant protein immobilised on ELISA plates were included because they were binding both peptide and full length Aβ specifically. pl454 (Human Aβ 33-40) was used as negative control peptide. Furthermore hybridomas were tested against p4374, pl323 and sAPP-alpha. Only hybridomas with good p4374, and pl323 binding and a lack of sAPP-alpha binding were used for further antibody development.
The Hybridoma clone MV-002 (internal name A115; IgG2b) was purified and analysed for specific detection of pl323, p4374, p4377, pl454, Aβ and sAPP-alpha respectively. MV-002 recognized the epitopes pl323 as well as p4377 and full length Aβ protein (recombinant protein; obtained from Bachem AG, Bubendorf, Switzerland) in ELISA. It however did not detect pl454 in ELISA. Furthermore, the MV-002 antibodies failed to detect sAPP-alpha but bound specifically to the peptide p4374 encoding the pyro- glutamate version of Aβll-19.
Example 7: Phage Display, in vitro binding and inhibition ELISA
Phage Display libraries used in this example were: Ph.D. 7: New England BioLabs E8102L (linear 7mer library) . Phage Display was done according to manufacturer' s protocol (www. neb . com) .
After 2 or 3 subsequent rounds of panning, single phage clones were picked and phage supernatants were subjected to ELISA on plates coated with the antibody that was used for the panning procedure. Phage clones that were positive in this ELISA (strong signal for the target, but no signal for unspecific control) were sequenced. From DNA sequences, peptide sequences were deduced. These peptides were synthesized and characterised in binding and inhibition ELISA. Additionally, some novel mimotopes were created by combining sequence information from mimotopes identified in the screen to support the identification of a consensus sequence for a mimotope vaccination.
1. In vitro binding assay (ELISA)
Peptides derived from Phage Display as well as variants thereof were coupled to BSA and bound to ELISA plates (iμM; as indicated in the respective figures) and subsequently incubated with the monoclonal antibody that was used for the screening procedure to analyse binding capacity of identified peptides.
2. In vitro inhibition assay (ELISA)
Different amounts of peptides (concentrations ranging from 10 μg to 0,08μg; serial dilutions; for MV-002: concentrations ranging from 5 μg to 0,03μg; serial dilutions), derived from Phage Display were incubated with the monoclonal antibody that was used for the screening procedure. Peptides diminishing subsequent binding of the antibody to the original epitope coated on ELISA plates were considered as inhibiting in this assay. Example 8: in vivo testing of mimotopes: analysis of immunogenicity and crossreactivity
1. In vivo testing of mimotopes
Inhibiting as well as non-inhibiting peptides were coupled to KLH and injected into mice (wildtype C57/B16 mice; subcutaneous injection into the flank) together with an appropriate adjuvant (aluminium hydroxide) . Animals were vaccinated 3-6 times in biweekly intervals and sera were taken biweekly as well. Titers to injected peptides, as well as to an irrelevant peptide were determined with every serum. Furthermore, titers against the recombinant human Aβ protein, and against original peptides were determined respectively. In general sera were analysed by reaction against peptides coupled to Bovine Serum Albumin (BSA) and recombinant full length proteins which were immobilised on ELISA plates. Titers were determined using anti mouse IgG specific antibodies. For detailed results see Figures 15, 16 and 17 respec- tively and Figures 23, 24 and 25 respectively. 2. Results for MV-OOl, MV-003 and MV-004
2.1. Identification of specific monoclonal antibodies (mAB) directed against n-terminally truncated and modified forms of A3:
Fig. 10 depicts the characterisation of the monoclonal antibody MV-OOl (internal name 824; IgGl) derived from experiment Alz-5 demonstrating specificity for full length Aβ and Aβ truncated at position E3.
Fig. 11 depicts the characterisation of the monoclonal antibody MV-003 (internal name D129; IgGl) derived from experiment Alz-16 demonstrating specificity for Aβ truncated and posttrans- lationally modified at position p(E)3.
Fig. 12 depicts the characterisation of the monoclonal antibody MV-004 (internal name B204; IgGl) derived from experiment Alz-15 demonstrating specificity for Aβ truncated at position Ell.
2.2. Screening with specific mABs directed against n~ terminally truncated and modified forms of AR:
2.2.1. Phage Display Library Ph.D. 7
2.2.1.1. Screening with monoclonal antibody directed against p4373
8 Sequences were identified by screening PhD 7 phage display libraries in this screen: Table IA summarises the peptides identified and their binding capacity as compared to the original epitope .
2.2.1.2. Screening with monoclonal antibody directed against p4372
9 Sequences were identified by screening PhD 7 phage display libraries in this screen: Table IB summarises the peptides identified and their binding capacity as compared to the original epitope .
2.2.1.3. Screening with monoclonal antibody directed against p4371
71 Sequences were identified by screening PhD 7 and PhD12 phage display libraries in this screen: Table 1C summarises the peptides identified and their binding capacity as compared to the original epitope.
Table IA: mimotopes binding to the parental antibody MV-003
Figure imgf000030_0001
Legend to Table IA: the binding capacity is coded by the following binding code: 1:X describes the dilution factor of the parental AB.
Figure imgf000030_0002
Table IB: mimotopes binding to the parental antibody MV-004
Figure imgf000030_0003
Figure imgf000031_0001
Legend to Table IB: the binding capacity is coded by the following binding code: 1:X describes the dilution factor of the parental AB.
Figure imgf000031_0002
Table 1C: mimotopes binding to the parental antibody MV-OOl
Figure imgf000031_0003
Figure imgf000032_0001
Figure imgf000033_0001
Legend to Table 1C: the binding capacity is coded by the following binding code: 1:X describes the dilution factor of the parental AB
Figure imgf000033_0002
2.3. In vitro characterisation of mimotopes identified in screening Phage Display Libraries with monoclonal antibodies directed against n-terminally truncated and modified forms of A3:
Figures 13 and 14 show representative examples for binding and inhibition assays used to characterise mimotopes in vitro. Data obtained are summarised in Tables 1 and 2 respectively.
MV-003 Mimotopes: From the 8 sequences presented 6 sequences inhibit binding of the p ( E) 3-7Aβ specific monoclonal antibody in in vitro competition experiments : Additional 2 sequences were identified that do not inhibit binding of monoclonal antibody in in vitro competition experiments but still retain binding capacity to the parental antibody (Table 2A) .
MV-004 Mimotopes : All the 9 sequences presented inhibit binding of the monoclonal antibody specifically binding the free N-terminus of Aβ truncated at position El l in in vitro competition experiments : ( Table 2B ) .
MV-O O l Mimotopes : From the 71 sequences presented 27 sequences inhibit binding of the monoclonal antibody specifically directed against Aβ truncated at position E3 in in vitro competition experiments : Additional 44 sequences were identif ied that do not inhibit binding of monoclonal antibody in in vitro competition experiments but still retain binding capacity to the parental antibody (Table 2C ) .
Table 2 : mimotopes identified in this invention giving positive results in inhibiting assays
Table 2A: MV-003 Mimotopes
Internal Peptide Sequence Inhibition Canumber pacity p4395 IRWDTPC 1 p4397 IRYDAPLC 1 p4728 IRWDTSLC n p4756 IRWDQPC 1
P4792 IRWDGC 1
P4793 IRWDGGC 1
Legend to Table 2A : the inhibition capacity is coded by the following code :
Weak inhibition means more peptide is required to lower AB binding than with the original epitope ; strong inhibition means s imilar peptide amounts are required for mimotope and original epitope for lowering AB binding . Mimotopes are compared to the original peptide as s tandard . OD at l Oug peptide used in the assay is used to calculate the compet ition capacity compared to original peptide .
Figure imgf000035_0001
Table 2B: MV-004 Mimotopes
Figure imgf000035_0002
Legend to Table 2B: the inhibition capacity is coded by the following code:
Weak inhibition means more peptide is required to lower AB binding than with the original epitope; strong inhibition means similar peptide amounts are required for mimotope and original epitope for lowering AB binding. Mimotopes are compared to the original peptide as standard. OD at lOug peptide used in the assay is used to calculate the competition capacity compared to original peptide.
Figure imgf000035_0003
Figure imgf000036_0001
Table 2C: MV-OOl Mimotopes
Figure imgf000036_0002
Figure imgf000037_0001
Legend to Table 2C: the inhibition capacity is coded by the following code:
Weak inhibition means more peptide is required to lower AB binding than with the original epitope; strong inhibition means similar peptide amounts are required for mimotope and original epitope for lowering AB binding. Mimotopes are compared to the original peptide as standard. OD at lOug peptide used in the assay is used to calculate the competition capacity compared to original peptide .
Figure imgf000037_0002
Table 3: Non-mimotope peptides
Figure imgf000037_0003
alpha-Secretase induced cleavage product desAPPalpha rived from human APP (gi: 112927)
2.4. In vivo characterisation of mimotopes identified in screening Phage Display Libraries with a monoclonal antibody directed against against n-terminally truncated and modified forms of A3:
Female C57/bl6 mice, 5-6 mice per group, were subcutaneously immunized with 30 μg peptide coupled to KLH. Control groups were administered original epitope-KLH conjugates respectively. As adjuvant alum was used (always 1 mg per mouse) . The peptides administered were all able to bind to monoclonal antibodies specifically although some of the peptides did not inhibit the binding of the original epitope to its parental antibody in vitro (in an in vitro inhibition assay) . The in vitro ELISA assay to determine the antibody titer was performed with sera of single mice after each vaccination in a two week interval (see Fig. 15 and 16 respectively) . The wells of the ELISA plate were coated with mimotope-BSA conjugate and an irrelevant peptide-BSA conjugate (negative control) . The positive control was performed by reaction of the parental antibody with the respective mimotope-BSA conjugate. The detection was performed with anti-mouse IgG. Additionally, recombinant proteins were immobilised on ELISA plates and sera reacted accordingly. Figures 15 to 17 show representative examples for assays used to characterise mimotopes in vivo.
Fig. 15 shows examples for in vivo characterisations of the immune response elicited by mimotope vaccination by analysing the immune response against injected peptide and an irrelevant peptide, containing an unrelated sequence. In all three examples shown, the original epitopes and the mimotopes, elicit immune responses against the injected peptides but fail to induce a relevant immune response against an unrelated sequence (pl454) .
As example for MV-003-mimotopes, original epitope p4373 and the mimotopes p4395, p4396, p4397, and p4399 are depicted in Fig. 15A. All vaccines are mounting similar immune responses against their respective mimotopes. Neither original epitope p4373-vaccine treated nor the animals treated with mimotope p4395, p4396, p4397 or p4399- vaccines mount relevant titers against irrelevant peptide pl454 (Hx -25x less than injected peptides) .
As example for MV-004-mimotopes original epitope p4372 and the mimotopes p4417, p4418, p4419, and p4420 are depicted in Fig. 15B. All vaccines are mounting similar immune responses against their respective mimotopes. Neither original epitope p4372-vaccine treated nor the animals treated with mimotope p4417, p4418, p4419, and p4420- vaccines mount relevant titers against irrelevant peptide pl454 (20-8Ox less than injected peptides) .
As example for MV-001-mimotopes original epitope p4371 and the mimotopes p4381, p4382, and p4390 are depicted in Fig. 15C. All vaccines are mounting similar immune responses against their respective mimotopes. Neither original epitope p4371-vaccine treated nor the animals treated with mimotope p4381, p4382, and p4390 - vaccines mount relevant titers against irrelevant peptide pl454 (>10x less than injected peptides) .
Fig. 16 shows examples for in vivo characterisations of the immune response elicited by mimotope vaccination against the respective original epitope of the parental antibody as well as against peptides derived of other forms of truncated species of Aβ.
As example for MV-003-mimotopes, original epitope p4373 and the mimotopes p4395, p4396, p4397, and p4399 are depicted in Fig. 16A. 3/4 Mimotope vaccines indicated mount detectable immune responses against the original epitope p4373. A similar phenomenon can be detected analysing cross reactivity against the non-modified form as displayed by p4371. The original epitope p4373-vaccine and 2/4 Mimotope vaccines mount relevant titers against p4371. Surprisingly, the mimotopes selected by MV-003, which is specifically binding to p4373 are also inducing a immune reaction cross reacting with the unmodified form of the original epitope.
As example for MV-004-mimotopes, original epitope p4372 and the mimotopes p4417, p4418, p4419, and p4420 are depicted in Fig. 16B. 3/4 Mimotope vaccines shown mount detectable immune responses against the original epitope p4372. As example for MV-001-mimotopes, original epitope p4371 and the mimotopes p4381, p4382, and p4390 are depicted in Fig. 16C. All Mimotope vaccines depicted mount detectable immune responses against the original epitope p4371. A similar phenomenon as described for MV-003 derived mimotopes can be detected analysing cross reactivity against the pyroglutamate-modified form as displayed by p4373. The original epitope p4371-vaccine and all Mimotope vaccines mount relevant titers against p4373. Surprisingly, the mimotopes selected by MV-OOl, which is specifically binding to p4371 are inducing a immune reaction cross reacting better with the modified form of the original epitope than the original epitope induced immune reaction or the parental antibody. Thus these mimotopes might surprisingly be able to induce but are not necessarily inducing a broader immune reaction than the parental antibody and can be used for a more wide targeting of forms of Aβ .
Fig. 17 shows examples for in vivo characterisations of the immune response elicited by mimotope vaccination against full length Aβ . Surprisingly, the mimotopes selected by using MV-OOl and MV-003 induce a cross reaction not only with the truncated or modified short epitopes used to create the antibodies but also induce cross reactivity to full length, non modified forms of Aβ as good as the original sequence or even more efficiently than p4371/p4373. For MV-002 original epitope as well as for the mimotopes identified, no such cross reactivity can be detected demonstrating a transfer of specificity of the antibody to the free N-Terminus of unmodified Aβll-40/42. Thus the mimotopes presented in this invention constitute optimised vaccine candidates to target a broad spectrum of naturally occurring forms of the Aβ peptides as have been found in the brain of AD patients. The forms include but are not limited to Aβl-40/42, and N- terminally truncated forms like Aβ3-40/42, Aβ (pE) 3-40/42 and unmodified Aβll-40/42 respectively.
In Table 4 and 5 further examples of the immune response elicited by mimotope vaccination against full length Aβ by using MV-001 and MV-003 derived mimotopes are described.
Table 4: In vivo characterisation of mimotopes : MV-001
Figure imgf000041_0002
All peptides listed in Table 4 mount specific immune reactions against full length and/or truncated and modified forms of Aβ or fragments thereof.
Table 5: In vivo characterisation of mimotopes : MV-003
Figure imgf000041_0001
All peptides listed in Table 5 mount specific immune reactions against full length and/or truncated and modified forms of Aβ or fragments thereof.
3. Results for MV-002
3.1. Identification of specific monoclonal antibodies (mAB) directed against n-terminally truncated and modified forms of Aβ:
Fig. 21 depicts the characterisation of the monoclonal antibody MV-002 (internal name A115; IgG2b) derived from experiment Alz-9 demonstrating specificity for full length Aβ and Aβ fragments truncated at position Ell and H14 and modified at position Ell to pEll.
3.2. Screening with specific mABs directed against n- terminally truncated and modified forms of Aβ :
3.2.1. Phage Display Library Ph.D. 7
3.2.1.1. Screening with monoclonal antibody directed against p!323
47 Sequences were identified by screening PhD 7 phage display libraries in this screen: Table 1 summarises the peptides identified and their binding capacity as compared to the original epitope.
Table 1: mimotopes binding to the parental antibody MV-002
Figure imgf000042_0001
- 4:
Figure imgf000043_0001
Legend to Table 1: the binding capacity is coded by the following binding code: 1:X describes the dilution factor of the parental AB. Ac-...indicates ac- etylated AA.
Figure imgf000044_0001
3.3. In vitro characterisation of mimotopes identified in screening Phage Display Libraries with monoclonal antibodies directed against n-terminally truncated and modified forms of Aβ :
Figures 21 and 22 show representative examples for binding and inhibition assays used to characterise mimotopes in vitro. Data obtained are summarised in Tables 1 and 2 respectively.
MV-002 Mimotopes: From the 47 sequences presented 11 sequences inhibited binding of the monoclonal antibody MV-002 in in vitro competition experiments. Additional 36 sequences were identified that did not inhibit binding of monoclonal antibody in in vitro competition experiments but still retained binding capacity to the parental antibody (Table 2) . Importantly, as described in Figures 23-25, the ability to compete with the original epitope for binding to the parental antibody in vitro was no prerequisite to mount specific immune responses cross reacting with specific peptides in vivo. Thus inhibiting as well as non- inhibiting peptides can be used for inducing immune responses detecting peptides in vivo (for details see: Figures 23-25) which can lead to clearance of amyloid peptides from the brain.
Table 2: mimotopes identified in this invention giving positive results in inhibiting assays; MV-002 Mimotopes
Figure imgf000044_0002
Figure imgf000045_0001
Legend to Table 2 : the inhibition capacity is coded by the following code :
Weak inhibition means more peptide is required to lower AB binding than with the original epitope ; strong inhibition means similar peptide amounts are required for mimotope and original epitope for lowering AB binding . Mimotopes are compared to the original peptide as standard . OD at 5ug peptide used in the assay is used to calculate the competition capacity compared to original peptide .
Figure imgf000045_0002
3 . 4 . In vivo characterisation of mimotopes identif ied in screening Phage Display Libraries with a monoclonal antibody directed against Amyloid Beta :
Female C57 /bl 6 mice , 5-6 mice per group , were subcutaneously immuni zed with 30 μg peptide coupled to KLH . Control groups were administered original epitope-KLH conj ugates respectively . As adj uvant alum was used ( always 1 rug per mouse ) . The peptides administered were all able to bind to monoclonal antibodies specifically although some of the peptides did not inhibit the binding of the original epitope to its parental antibody in vitro ( in an in vitro inhibition assay ) . The in vitro ELI SA assay to determine the antibody titer was performed with sera of sin- gle mice after each vaccination in a two week interval (see Fig. 25 and 26 respectively) . Titers were calculated as OD max/2 in all figures shown. The wells of the ELISA plate were coated with mimotope-BSA conjugate and an irrelevant peptide-BSA conjugate (negative control) . The positive control was performed by reaction of the parental antibody with the respective mimotope-BSA conjugate. The detection was performed with anti-mouse IgG. Additionally, recombinant proteins were immobilised on ELISA plates and sera reacted accordingly. Figures 23, 24 and 25 show representative examples for assays used to characterise rnimo- topes in vivo. The results depicted were derived from peptides active in in vitro inhibition assays like p4670, p4675, p4680, and p4681 and a peptide without inhibition capacity, p4403 respectively.
Fig. 23 shows examples for in vivo characterisations of the immune response elicited by mimotope vaccination by analysing the immune response against injected peptide and an irrelevant peptide, containing an unrelated sequence. In the examples shown, the epitope p4377 and the mimotopes p4670, p4675, p4680, p4681 and p4403 elicited immune responses against the injected peptides but failed to induce a relevant unspecific immune response against an unrelated sequence (pl454) .
Fig. 24 shows examples for in vivo characterisations of the immune response elicited by mimotope vaccination against the respective original epitope of the parental antibody (p4377) as well as against peptides derived from truncated species of Aβ(pl323 and p4374)and against sAPP alpha. p4377 and the mimotopes p4670, p4675, p4680, p4681 and p4403 mounted detectable immune responses against the original epitope p4377. A similar phenomenon could be detected analysing cross reactivity against the modified form as displayed by p4374. Interestingly, the original epitope and the mimotope vaccines mounted relevant titers against p4374 the modified form of the original epitope. Surprisingly, the mimotopes seemed to be able to induce but did not necessarily induce a more efficient immune response against pl323 indicating a potential to induce a broader immuno-reactivity as compared to the original Aβ fragment. Additionally, no reactivity was detectable against sAPP alpha. Fig. 25 shows examples for in vivo characterisations of the immune response elicited by mimotope vaccination against full length Aβ . Surprisingly, the mimotopes selected by using MV-002 induced a cross reaction not only with the truncated or modified short epitopes used to create the antibodies but also induced cross reactivity to full length, non modified forms of Aβ as good as the original sequence or even more efficiently than p4377.
Interestingly competing as well as non competing peptides were able to induce similar immune responses specifically interacting with peptides containing original Aβ sequences. Thus the mimotopes presented in this invention constitute optimised, novel vaccine candidates to target a broad spectrum of naturally occurring forms of the Aβ peptides as have been found in the brain of AD patients. The forms include but are not limited to Aβl-40/42, and N-terminally truncated forms like Aβ3-40/42, Aβ (pE)3-40/42, unmodified Aβll-40/42, modified Aβp (E) 11-40/42 and Aβl4-40/42 respectively. Importantly, the mimotopes presented also did not induce a cross reactivity to the neoepitopes present in sAPP alpha after cleavage from APP and thus do not interfere with normal sAPP alpha signalling (see Fig. 24 for details) .
Table 3: Non-Mimotope peptides used
Figure imgf000047_0001
- A l -
In Table 4 further examples of the immune response elicited by mimotope vaccination against full length Aβ by using MV-002 derived mimotopes are described. All peptides listed in table 4 mount specific immune reactions against full length and/or truncated and modified forms of Aβ or fragments thereof.
Table 4: In vivo characterisation of mimotopes : MV-002
Figure imgf000048_0001
Example 9: In vivo characterisation of mimotopes for the efficacy to reduce AD like disease in transgenic animals
The Tg2576 AD mouse model was used to study the preclinical efficacy of the mimotope vaccines. This transgenic line is expressing human APP carrying the Swedish double mutation at aa position 670/671 under the control of a hamster prion protein (PrP) promoter which results in overexpression of the protein. It is currently one of the most widely employed models in AD research. The Tg2576 model recapitulates various hallmarks of AD pathology including disease-specific amyloid plaque deposition and astrocytosis. As all other AD model systems available to date, it does not reflect all cardinal neuropathological features of AD.
To assess whether treatment with mimotopes. is capable of preventing cerebral Aβ accumulation, Tg2576 mice were s.c. injected 6 times at monthly intervals with peptide-KLH conjugates adsorbed to ALUM (adjuvant: aluminium hydroxide) or PBS adsorbed to ALUM (referred to as PBS or control) alone. Up to eight weeks after the last immunization, animals were sacrificed, their brains harvested and analyzed for their Aβ load (AD-like pathology) . The mice were sacrificed under deep anaesthesia. Subsequently, the brain was isolated, fixed in 4%PFA and dehydrated by graded Ethanol series followed by incubation in Xylene and paraffin embedding. Each paraffin-embedded brain was sectioned at 7μM using a slicing microtome and sections were mounted on glass slides.
As a method to assay AD-like pathology in Tg2576 animals, the relative area occupied by amyloid deposits in the brain of treated animals was analyzed. This analysis was performed using an automated area recognition programme. To identify the plaques, sections were stained with the monoclonal antibody
(mAb) 3A5 (specific for Aβ40/42) . Mimotope treated animals were compared to control animals. All animals have been sacrificed at an age of 13,5-14 months. For this analysis 3 slides/animal covering the cortex and hippocampus were selected, stained with mAb 3A5 and subsequently documented using the Mirax-system
(Zeiss) . For the calculation of the area occupied by amyloid plaques, up to four individual sections per slide were analysed and sections carrying tissue artefacts and aberrant staining intensities have been excluded after inspection of the result pictures .
For the mimotopes derived from MVOOl an area analysis using three exemplary candidates was performed: Analysis was performed following repeated vaccination using peptide-KLH conjugate vaccines. The control group showed an average occupation of 0,35% as compared to 0,11%, 0,14% and 0,22% for the mimotope treated animals respectively. This corresponds to a reduction following mimotope treatment of 67% in group 2, a 60% reduction in group 3 and a 36% reduction in group 4 (see Fig. 18) . For the mimotopes of MV002 an area analysis using one exemplary candidate was performed: Analysis was performed following repeated vaccination using peptide-KLH conjugate vaccines. The control group showed an average occupation of 0,35% as compared to 0,24% for the mimotope treated animals respectively. This corresponds to a reduction following mimotope treatment of 31% in group 2.
A similar picture can be detected for the group of MV003 derived mimotopes. Here the example of p4395 is depicted. As described for the MVOOl derived mimotopes, an analysis of the area occupied by amyloid plaques following peptide-conjugate vaccination has been performed. The control group showed an average occupation of 0,35% as compared to 0,21% for the mimotope treated animals respectively. This corresponds to a reduction following mimotope treatment of 38% in group 2 (see Fig. 19) .
Thus, this set of data clearly indicates a beneficial effect of mimotope vaccine treatment on AD like pathology in transgenic animals .
Example 10: In vivo characterisation of mimotopes for the efficacy to reduce PD like disease in transgenic animals (proof of concept analysis)
The double transgenic mouse model (mThyl-APP751 (line TASD41) crossed with mThyl-wt human a-syn (Line TASD 61)) was used to study the preclinical efficacy of AD mimotope vaccines to reduce PD like disease. The model recapitulates various hallmarks of AD and PD pathology including disease-specific amyloid plaque deposition and astrocytosis as well as synuclein aggregation and cell loss.
To assess whether treatment with mimotopes is capable of ameliorating PD like disease, transgenic mice were s.c. injected 6 times at monthly intervals with peptide-KLH conjugates adsorbed to ALUM (adjuvant: aluminium hydroxide) or PBS adsorbed to ALUM (referred to as PBS or control) alone. After the last immunization, animals were sacrificed following guidelines for the humane treatment of animals. Subsequently, the brain was isolated, fixed and sectioned at 40μM using a vibratome and sections were stored at -2O0C in cryoprotective medium. Sections were immunostained with antibodies against α-synuclein and NeuN (neuronal marker) and imaged with the laser confocal microscope. Digital images were analyzed with the ImageQuant program to assess numbers of α-synuclein aggregates and neurons. Mimotope treated animals were compared to control animals. Results depict an exemplary set of data for a mimotope described in this invention
In order to analyse whether vaccination with AD mimotopes would result in a reduction of PD associated pathology the incidence of neuronal inclusions of α-synuclein in the frontal cortex and the hippocampus was analysed (Lewy body like inclusions) . Animals overexpressing APP and α-synuclein in the brain developed pathologic alterations reminiscent of PD. α-synuclein positive neuronal inclusions are depicted in Fig. 27 as spots in neuronal bodies. A quantitative analysis of the inclusions revealed that the levels of accumulation of α-synuclein in the neuronal cell bodies in the neocortex and hippocampus were significantly reduced in the double transgenic mice following AD mimotope vaccination. This reduction amounted to 32,7% in the cortex (p=0,0001) indicating a beneficial effect of AD mimotope vaccination on PD like pathology in this area.
As a second method to assay PD-like pathology in transgenic animals, the number of neurons in the cortex and hippocampus of treated animals by NeuN staining was analysed.
In this animal model a progressive loss of neurons in the frontal cortex as well as in the hippocampus upon ageing can be detected. Quantification of the neuronal density in the frontal cortex and the hippocampus showed a slight decrease in double transgenic PBS treated mice as compared to non transgenic control animals. This slight reduction indicates neurodegeneration in the strain used for this experiment.
Interestingly, mice treated with an AD mimotope (Fig.28) showed levels of NeuN positive neurons, which were comparable to controls. Double Tg animals revealed a statistically significant 27% increase (p=0,044) in the hippocampus as compared to the carrier treated controls respectively. In the cortical area, a 28, 4% (p=0, 0053) increase in the double Tg animals could be observed following AD mimotope treatment. This relative increase as compared to the vehicle treated animals could also be interpreted as an indication of reduced neurodegeneration in successfully treated animals.
Summarizing, this set of data clearly indicates a beneficial effect of AD mimotope vaccine treatment on PD like symptoms in transgenic animals.

Claims

Claims :
1. Compound comprising a peptide for treating, preventing and/or ameliorating motor symptoms of Parkinson's disease, said peptide having a binding capacity to an antibody which is specific for an epitope of the amyloid-beta-peptide (Aβ) .
2. Compound according to claim 1, characterised in that said epitope of the amyloid-beta-peptide is selected from the group consisting of DAEFRH, EFRHDSGY, pEFRHDSGY, EVHHQKL, HQKLVF and HQKLVFFAED.
3. Compound according to claim 1 or 2, characterised in that said peptide has not the amino acid sequence DAEFRH, EFRHDSGY, pEFRHDSGY, EVHHQKL, HQKLVF and HQKLVFFAED.
4. Compound according to any one of claims 1 to 3, characterised in that said peptide comprises the amino acid sequence
X1X2X3X4X5X6X7, (Formula I)
wherein Xi is G or an amino acid with a hydroxy group or a negatively charged amino acid, preferably glycine (G) , glutamic acid (E) , tyrosine (Y) , serine (S) or aspartic acid (D) ,
X2 is a hydrophobic amino acid or a positively charged amino acid, preferably asparagine (N), isoleucine (I), leucine (L), valine (V) , lysine (K) , tryptophane (W) , arginine (R) , tyrosine (Y), phenylalanine (F) or alanine (A),
X3 is a negatively charged amino acid, preferably aspartic acid (D) or glutamic acid (E) ,
X4 is an aromatic amino acid or a hydrophobic amino acid or leucine (L) , preferably tyrosine (Y) , phenylalanine (F) or leucine (L) ,
X5 is histidine (H) , lysine (K) , tyrosine (Y) , phenylalanine (F) or arginine (R), preferably histidine (H), phenylalanine (F) or arginine (R) , and
X6 is not present or serine (S) , threonine (T) , asparagine (N), glutamine (Q), aspartic acid (D), glutamic acid (E), arginine (R), isoleucine (I), lysine (K), tyrosine (Y), or glycine (G)/ preferably threonine (T), asparagine (N), aspartic acid (D), arginine (R), isoleucine (I) or glycine (G),
X7 is not present or any amino acid, preferably proline (P), tyrosine (Y) , threonine (T) , glutamine (Q) , alanine (A) , his- tidine (H) or serine (S) , preferably EIDYHR, ELDYHR, EVDYHR, DIDYHR, DLDYHR, DVDYHR, DI-DYRR, DLDYRR, DVDYRR, DKELRI, DWELRI, YREFFI, YREFRI, YAEFRG, EAEFRG, DYEFRG, ELEFRG, DRELRI, DKELKI, DRELKI, GREFRN, EYEFRG, DWEFRDA, SWEFRT, DKELR, SFEFRG, DAEFRWP, DNEFRSP, GSEFRDY, GAEFRFT, SAEFRTQ, SAEFRAT, SWEFRNP, SWEFRLY, SWELRQA, SVEFRYH, SYEFRHH, SQEFRTP, SSEFRVS, DWEFRD, DAELRY, DWELRQ, SLEFRF, GPEFRW, GKEFRT, AYEFRH, DKE(NIe)R, DKE(Nva)R or DKE(Cha)R.
5. Compound according to any one of claims 1 to 3, characterised in that said peptide comprises the amino acid sequence
XlRX2DX3(X4)n(X5)m(X6)o, (Formula II),
wherein X1 is isoleucine (I) or valine (V),
X2 is tryptophan (W) or tyrosine (Y) ,
X3 is threonine (T) , valine (V) , alanine (A) , methionine (M) , glutamine (Q) or glycine (G) ,
X4 is proline (P) , alanine (A) , tyrosine (Y) , serine (S) , cysteine (C) or glycine (G) ,
X5 is proline (P), leucine (L), glycine (G) or cysteine (C),
Xβ is cysteine (C) , n, m and o are, independently, 0 or 1, preferably IRWDTP(C), VRWDVYP(C), IRYDAPL(C), IRYDMAG(C), IRWDTSL(C), IRWDQP(C), IRWDG(C) or IRWDGG(C) .
6. Compound according to any one of claims 1 to 3, characterised in that said peptide comprises the amino acid sequence
EXiWHX2X3(X4)n(X5)m (Formula III),
wherein Xi is valine (V) , arginine (R) or leucine (L) ,
X2 is arginine (R) or glutamic acid (E) ,
X3 is alanine (A) , histidine (H) , lysine (K) , leucine (L) , tyrosine (Y) or glycine (G) ,
X4 is proline (P), histidine (H), phenylalanine (F) or glutamine (Q) or Cysteine X5 is cysteine (C) , n and m are, independently, 0 or 1, preferably EVWHRHQ(C) , ERWHEKH(C), EVWHRLQ(C), ELWHRYP(C), ELWHRAF(C), ELWHRA(C), EVWHRG(C), EVWHRH(C) and ERWHEK(C), preferably EVWHRHQ(C), ERWHEKH(C), EVWHRLQ(C), ELWHRYP(C) or EL- WHRAF(C) .
7. Compound according to any one of claims 1 to 3, characterised in that said peptide comprises the amino acid sequence QDFRHY(C), SEFKHG(C), TSFRHG(C), TSVFRH(C), TPFRHT(C), SQFRHY(C), LMFRHN(C), SAFRHH(C), LPFRHG(C), SHFRHG(C), ILFRHG(C), QFKHDL(C), NWFPHP(C), EEFKYS(C), NELRHST(C), GEMRHQP(C), DTYFPRS(C), VELRHSR(C), YSMRHDA(C), AANYFPR(C), SPNQFRH(C), SSSFFPR(C), EDWFFWH(C), SAGSFRH(C), QVMRHHA(C), SEFSHSS(C), QPNLFYH(C), ELFKHHL(C), TLHEFRH(C), ATFRHSP(C), AP- MYFPH(C), TYFSHSL(C), HEPLFSH(C), SLMRHSS(C), EFLRHTL(C), ATPLFRH(C), QELKRYY(C), THTDFRH(C), LHIPFRH(C), NELFKHF(C), SQYFPRP(C), DEHPFRH(C), MLPFRHG(C), SAMRHSL(C), TPLMFWH(C), LQFKHST(C), ATFRHST(C), TGLMFKH(C), AEFSHWH(C), QSEFKHW(C), AEFMHSV(C), ADHDFRH(C), DGLLFKH(C), IGFRHDS(C), SNSEFRR(C), SELRHST(C), THMEFRR(C), EELRHSV(C), QLFKHSP(C), YEFRHAQ(C), SNFRHSV(C), APIQFRH(C), AYFPHTS(C), NSSELRH(C), TEFRHKA(C), TSTEMWH(C), SQSYFKH(C), (C)SEFKH, SEFKH(C), (C)HEFRH or HEFRH(C) .
8. Compound according to any one of claims 1 to 3, characterised in that said peptide comprises the amino acid sequence
(Xl)mGX2X3X4FX5X6(X7)n (Formula IV),
wherein Xi is serine (S), alanine (A) or cysteine (c) ,
X2 is serine (S), threonine (T), glutamic acid (E), aspartic acid (D), glutamine (Q) or methionine (M),
X3 is isoleucine (I), tyrosine (Y), methionine (M) or leucine (L) ,
X4 is leucine (L) , arginine (R) , glutamine (Q) , tryptophan (W), valine (V), histidine (H), tyrosine (Y), isoleucine (I), lysine (K) methionine (M) or phenylalanine (F),
X5 is alanine (A), phenylalanine (F), histidine (H), aspar- agine (N), arginine (R), glutamic acid (E), isoleucine (I), glutamine (Q), aspartic acid (D), proline [P) or tryptophane (W), glycine (G)
Xe is any amino acid residue, X7 is cysteine (C) , m and n are, independently, 0 or 1, preferably SGEYVFH(C) , SGQLKFP(C), SGQIWFR(C), SGEIHFN(C), GQIWFIS(C), GQIIFQS(C), GQIRFDH(C), GEMWFAL(C), GELQFPP(C), GELWFP(C), GEMQFFI(C), GELYFRA(C), GEIRFAL(C), GMIVFPH(C),
GEIWFEG(C), GDLKFPL(C) GQILFPV(C) GELFFPK(C) , GQIMFPR(C) ,
GSLFFWP (C) , GEILFGM (C) GQLKFPF(C) GTIFFRD(C) , GQIKFAQ(C) ,
GTLIFHH(C), GEIRFGS(C) GQIQFPL(C) GEIKFDH(C) , GEIQFGA(C) ,
GELFFEK(C), GEIRFEL(C) GEIYFER(C) SGEIYFER(C; AGEIYFER(C; or
(C)GEIYFER.
9. Compound according to any one of claims 1 to 3, characterised in that said peptide comprises the amino acid sequence
(Xl)mHX2X3X4X5FX6(X7)n (Formula V) ,
wherein X]_ is serine (S) , threonine (T) or cysteine (C) ,
X2 is glutamine (Q) , threonine (T) or methionine (M) ,
X3 is lysine (K) or arginine (R) ,
X4 is leucine (L) , methionine (M) ,
X5 is tryptophane (W), tyrosine (Y), phenylalanine (F) or isoleucine (I) ,
XQ is asparagine (N) , glutamic acid (E) , alanine (A) or cysteine (C) ,
X7 is cysteine (C) , n and m are, independently, 0 or 1, preferably SHTRLYF(C), HMRLFFN(C), SHQRLWF(C), HQKMIFA(C), HMRMYFE(C), THQRLWF(C) or HQKMIF(C) .
10. Compound according to any one of claims 1 to 3, characterised in that said peptide comprises the amino acid sequence AIPLFVM(C), KLPLFVM(C), QLPLFVL(C) or NDAKIVF(C) .
11. Compound according to any one of claims 1 to 10, characterised in that the compound is a polypeptide and comprises 4 to 30 amino acid residues.
12. Compound according to any one of claims 1 to 11, characterised in that the compound is coupled to a pharmaceutically acceptable carrier, preferably KLH (Keyhole Limpet Hemocyanin) .
13. Compound according to any one of claims 1 to 12, characterised in that the compound is formulated for subcutaneous, intradermal or intramuscular administration.
14. Compound according to any one of claims 1 to 13, characterised in that the compound is formulated with an adjuvant, preferably aluminium hydroxide.
15. Compound according to any one of claims 1 to 14, characterised in that the compound is contained in the medicament in an amount of from 0.1 ng to 10 mg, preferably 10 ng to 1 mg, in particular 100 ng to 10 μg .
16. Compound according to any one of claims 1 to 15, characterised in that the motor symptoms of Parkinson's disease are selected from the group consisting of resting tremor, Bradykine- sia, rigidity, postural instability, stooped posture, dystonia, fatigue, impaired fine motor dexterity and motor coordination, impaired gross motor coordination, poverty of movement (decreased arm swing) , akathisia, speech problems, loss of facial expression, micrographia, difficulty swallowing, sexual dysfunction and drooling.
17. Use of a compound according to any one of claims 1 to 12 for the manufacture of a medicament for treating, preventing and/or ameliorating motor symptoms of Parkinson's disease.
PCT/AT2009/000237 2008-06-12 2009-06-12 Compounds for treating symptoms associated with parkinson's disease WO2009149487A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN2009801313674A CN102123726A (en) 2008-06-12 2009-06-12 Compounds for treating symptoms associated with parkinson's disease
MX2010013647A MX2010013647A (en) 2008-06-12 2009-06-12 Compounds for treating symptoms associated with parkinson's disease.
CA2723995A CA2723995A1 (en) 2008-06-12 2009-06-12 Compounds for treating symptoms associated with parkinson's disease
EP20090761154 EP2310032A2 (en) 2008-06-12 2009-06-12 Compounds for treating symptoms associated with parkinson's disease
US12/997,702 US20110092436A1 (en) 2008-06-12 2009-06-12 Compounds for treating symptoms associated with parkinson's disease
BRPI0915134A BRPI0915134A2 (en) 2008-06-12 2009-06-12 compound and use of a compound
JP2011512782A JP2011522842A (en) 2008-06-12 2009-06-12 Compounds for the treatment of symptoms associated with Parkinson's disease
AU2009257170A AU2009257170B2 (en) 2008-06-12 2009-06-12 Compounds for treating symptoms associated with Parkinson's disease
IL209896A IL209896A0 (en) 2008-06-12 2010-12-09 Compounds for treating symptoms associated with parkinson's disease
US13/770,594 US20130287807A1 (en) 2008-06-12 2013-02-19 Compounds for treating symptoms associated with parkinson's disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AT0095208A AT506820B1 (en) 2008-06-12 2008-06-12 VZZINE AGAINST ALZHEIMER DISEASE
AT0095108A AT506819B1 (en) 2008-06-12 2008-06-12 VACCINE FOR THE TREATMENT OF ALZHEIMER DISEASE
ATA951/2008 2008-06-12
ATA952/2008 2008-06-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/770,594 Division US20130287807A1 (en) 2008-06-12 2013-02-19 Compounds for treating symptoms associated with parkinson's disease

Publications (2)

Publication Number Publication Date
WO2009149487A2 true WO2009149487A2 (en) 2009-12-17
WO2009149487A3 WO2009149487A3 (en) 2010-07-29

Family

ID=41417160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2009/000237 WO2009149487A2 (en) 2008-06-12 2009-06-12 Compounds for treating symptoms associated with parkinson's disease

Country Status (12)

Country Link
US (2) US20110092436A1 (en)
EP (1) EP2310032A2 (en)
JP (1) JP2011522842A (en)
KR (1) KR20110036809A (en)
CN (1) CN102123726A (en)
AU (1) AU2009257170B2 (en)
BR (1) BRPI0915134A2 (en)
CA (1) CA2723995A1 (en)
IL (1) IL209896A0 (en)
MX (1) MX2010013647A (en)
RU (1) RU2011100127A (en)
WO (1) WO2009149487A2 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013050249A1 (en) 2011-10-04 2013-04-11 Affiris Ag METHOD FOR DETECTING Aß-SPECIFIC ANTIBODIES IN A BIOLOGICAL SAMPLE
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
US8679498B2 (en) 2010-08-12 2014-03-25 Eli Lilly And Company Anti-N3PGLU amyloid beta peptide antibodies and uses thereof
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2015185602A1 (en) * 2014-06-04 2015-12-10 Affiris Ag Treatment and prevention of parkinson's disease (pd)
WO2017079833A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
US9944696B2 (en) 2016-01-15 2018-04-17 Eli Lilly And Company Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
WO2019014768A1 (en) 2017-07-18 2019-01-24 The University Of British Columbia Antibodies to amyloid beta
US10647759B2 (en) 2017-04-20 2020-05-12 Eli Lilly And Company Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
US10751382B2 (en) 2016-11-09 2020-08-25 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US11312763B2 (en) 2016-07-01 2022-04-26 Eli Lilly And Company Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
US11970522B2 (en) 2020-08-28 2024-04-30 The University Of British Columbia Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016131420A1 (en) * 2015-02-17 2016-08-25 上海交通大学医学院附属上海儿童医学中心 Mutant gene related to drug resistance and relapse of acute lymphoblastic leukaemia and use thereof
CN106632607A (en) * 2016-12-29 2017-05-10 华东理工大学 Targeting survivin nano antibody as well as preparation method and application thereof
CN108191966B (en) * 2018-01-11 2020-10-27 桂林医学院 Polypeptide containing lead peptide capable of passing blood brain barrier to chelate iron in brain and reduce free radicals
CN110156887B (en) * 2018-02-12 2023-01-13 中国人民解放军军事科学院军事医学研究院 Human VASN protein antigen epitope, antigen mimic epitope and application thereof
CN108676071B (en) * 2018-05-24 2021-05-14 华南理工大学 anti-Abeta protein aggregation heptapeptide, application thereof and gene for encoding synthetic polypeptide
CN108676072B (en) * 2018-05-24 2021-05-14 华南理工大学 Polypeptide with anti-Abeta 42 protein aggregation function, application thereof and gene for encoding polypeptide
CN111040020B (en) * 2018-12-28 2022-04-12 中国人民解放军军事科学院军事医学研究院 Alkene thioether staple peptide and preparation method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041067A2 (en) * 2002-11-01 2004-05-21 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic disease
WO2004062556A2 (en) * 2003-01-14 2004-07-29 Frank Mattner Methods for preventing and treating alzheimer’s disease (ad)
WO2006005707A2 (en) * 2004-07-13 2006-01-19 Affiris Forschungs- Und Entwicklungs Gmbh Method for preventing and treating alzheimer´s disease
WO2006083689A2 (en) * 2005-01-28 2006-08-10 Elan Pharma International Limited Anti a beta antibody formulation
US20060280743A1 (en) * 2000-12-06 2006-12-14 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02007796A (en) * 2000-02-21 2003-12-08 Pharmexa As Novel method for down regulation of amyloid.
US20040067535A1 (en) * 2002-10-03 2004-04-08 Life Sciences Development Corp. Alzheimer's disease linked genes
US20040265849A1 (en) * 2002-11-22 2004-12-30 Applera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
US20050176030A1 (en) * 2003-10-28 2005-08-11 Li Gan Regulated nucleic acids in pathogenesis of Alzheimer's Disease
JP2005330231A (en) * 2004-05-20 2005-12-02 Otsuka Pharmaceut Co Ltd Pharmaceutical composition
WO2009102694A1 (en) * 2008-02-12 2009-08-20 Bristol-Myers Squibb Company Heterocyclic derivatives as hepatitis c virus inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060280743A1 (en) * 2000-12-06 2006-12-14 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
WO2004041067A2 (en) * 2002-11-01 2004-05-21 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic disease
WO2004062556A2 (en) * 2003-01-14 2004-07-29 Frank Mattner Methods for preventing and treating alzheimer’s disease (ad)
WO2006005707A2 (en) * 2004-07-13 2006-01-19 Affiris Forschungs- Und Entwicklungs Gmbh Method for preventing and treating alzheimer´s disease
WO2006083689A2 (en) * 2005-01-28 2006-08-10 Elan Pharma International Limited Anti a beta antibody formulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200581 Thomson Scientific, London, GB; AN 2005-792379 XP002572675 & JP 2005 330231 A (OTSUKA PHARM CO LTD) 2 December 2005 (2005-12-02) *
J-M M: "Don d'organes" REVUE FRANCOPHONE DES LABORATOIRES, ELSEVIER, AMSTERDAM, NL, vol. 2008, no. 400, 1 January 2008 (2008-01-01), page 14, XP022667611 ISSN: 1773-035X [retrieved on 2008-01-01] *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679498B2 (en) 2010-08-12 2014-03-25 Eli Lilly And Company Anti-N3PGLU amyloid beta peptide antibodies and uses thereof
US8961972B2 (en) 2010-08-12 2015-02-24 Eli Lilly And Company Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
WO2013050249A1 (en) 2011-10-04 2013-04-11 Affiris Ag METHOD FOR DETECTING Aß-SPECIFIC ANTIBODIES IN A BIOLOGICAL SAMPLE
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
WO2013164357A1 (en) * 2012-05-01 2013-11-07 Affiris Ag Compositions
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2015185602A1 (en) * 2014-06-04 2015-12-10 Affiris Ag Treatment and prevention of parkinson's disease (pd)
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US11905318B2 (en) 2015-11-09 2024-02-20 The University Of British Columbia Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide
WO2017079833A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US9944696B2 (en) 2016-01-15 2018-04-17 Eli Lilly And Company Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
US11312763B2 (en) 2016-07-01 2022-04-26 Eli Lilly And Company Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
US10751382B2 (en) 2016-11-09 2020-08-25 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US11779629B2 (en) 2016-11-09 2023-10-10 The University Of British Columbia Compositions comprising cyclic peptides derived from an A-beta peptide
US10647759B2 (en) 2017-04-20 2020-05-12 Eli Lilly And Company Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
US11078261B2 (en) 2017-04-20 2021-08-03 Eli Lilly And Company Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
WO2019014768A1 (en) 2017-07-18 2019-01-24 The University Of British Columbia Antibodies to amyloid beta
US11970522B2 (en) 2020-08-28 2024-04-30 The University Of British Columbia Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide

Also Published As

Publication number Publication date
KR20110036809A (en) 2011-04-11
EP2310032A2 (en) 2011-04-20
AU2009257170A1 (en) 2009-12-17
US20110092436A1 (en) 2011-04-21
BRPI0915134A2 (en) 2016-02-16
US20130287807A1 (en) 2013-10-31
WO2009149487A3 (en) 2010-07-29
MX2010013647A (en) 2011-04-05
CN102123726A (en) 2011-07-13
IL209896A0 (en) 2011-02-28
RU2011100127A (en) 2012-07-20
CA2723995A1 (en) 2009-12-17
AU2009257170B2 (en) 2014-06-12
JP2011522842A (en) 2011-08-04

Similar Documents

Publication Publication Date Title
JP6041917B2 (en) Compounds for treating diseases
US20130287807A1 (en) Compounds for treating symptoms associated with parkinson's disease
US11534484B2 (en) Mimotopes of alpha-synuclein and vaccines thereof for the treatment of synucleinopathy
JP5989074B2 (en) Compounds for the treatment of amyloidosis
US8828942B2 (en) Means for treating synucleinopathies

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980131367.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09761154

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2723995

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 209896

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/013647

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2011512782

Country of ref document: JP

Ref document number: 12997702

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 9022/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009257170

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009761154

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20117000819

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011100127

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2009257170

Country of ref document: AU

Date of ref document: 20090612

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0915134

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101210